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Abstract 
 
Biological and clinical findings show that the variation in the angiogenesis, lymph-
angiogenesis and metastasis processes may affect patient survival. This study aims to identify 
new prognostic markers in colorectal cancer by investigating the associations of 381 genetic 
polymorphisms and haplotypes from 30 angiogenesis, lymph-angiogenesis and metastasis genes 
in a cohort of colorectal cancer patients from Newfoundland and Labrador. Our results showed 
that three linked SNPs located in the MMP8 and MMP27 genes were individually associated 
with overall survival (rs11225388, rs11225389, and rs12365082). By predicting and analyzing 
the haplotypes from these genes I also found an association between overall survival and an 
MMP3 haplotype consisting of four polymorphisms. The biological consequences of these three 
SNPs and the MMP3 haplotype and their relation to the risk of death in colorectal cancer are 
currently unknown. Future studies are required to replicate these findings in another cohort of 
colorectal cancer patients. 
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Chapter 1 
 
1.1 Overview of the research study 
Colorectal cancer is the fourth most common cause of cancer-related death worldwide 
accounting for over 9% of all cancers diagnosed (1, 2). The highest incidence of this 
disease in Canada is observed in Newfoundland and Labrador (NL) (3). The majority of 
colorectal cancers are sporadic while 5% to 10% of colorectal cancers are due to inherited 
mutations (4). Risk factors for colorectal cancer are classified as modifiable such as 
personal behavior and lifestyle factors or non-modifiable, such as age, family history, 
genetic factors and personal medical history (5). 
Many factors that affect the outcome of colorectal cancer have been identified, but 
few of them have been robust or informative enough to provide guidance for clinical 
management. Prognostic factors that are well supported by research and that are used in 
patient management include tumor stage, age of diagnosis, regional node involvement, 
and residual tumor (6). In addition, many genetic markers have been identified as having 
prognostic or predictive utility for colorectal cancer outcome, but none have yet been 
integrated into patient management (6).  
Recent studies have aimed to identify the genetic basis of prognostic variation in 
cancer patients. These studies usually investigate genetic variations, such as single 
nucleotide polymorphisms (SNPs), and their potential association with survival times. 
Among the candidate genes for such studies are the genes functioning in the angiogenesis, 
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lymph-angiogenesis and metastasis pathways. Angiogenesis is the growth of new blood 
vessels (7) while lymph-angiogenesis refers to the formation of new lymphatic vessels 
(8). Variations in these pathways may affect local tumor progression and distant 
metastasis (9, 10). Several genes, such as matrix metalloproteinases, have also been 
identified which may facilitate development of distant metastases in cancer patients.  
The use of genetic polymorphisms such as SNPs and their combinations in 
haplotypes has helped to identify the genetic variations that can affect individual 
susceptibility to common complex diseases (11-13). Similar approaches, albeit in fewer 
studies, have been applied to identify genetic variations that are associated with the 
survival of cancer patients (14, 15).  
The focus of this current research study is to analyze genetic polymorphisms and 
haplotypes in select candidate genes functioning in the angiogenesis, lymph-angiogenesis, 
and metastasis pathways in relation to survival outcomes of colorectal cancer patients. I 
tested the association of 381 polymorphisms and gene-based haplotypes with overall 
survival and disease-free survival in a cohort of 505 colorectal cancer patients from 
Newfoundland. 
 
1.2. Introduction to colorectal cancer 
Colorectal cancer is a disease caused by uncontrolled growth of cells within the 
colon or rectum (16). It is one of the most common gastrointestinal tract malignancies 
with a high incidence worldwide, especially in the developed countries (2, 17).  
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The development of colorectal cancer is a complex process involving multiple 
molecular pathways. Generally colorectal tumor growth is slow, yet tumors can spread to 
surrounding and distant tissues of the body (18). Since there may be no symptoms of 
colorectal cancer until late in the course of the disease, it is often diagnosed at an 
advanced stage (19). The prognosis in colorectal cancer varies with the extent of the 
disease at diagnosis: patients with early stage of the disease have longer survival times 
than those diagnosed with late stage and metastatic disease (20, 21). In recent years, 
mortality rates have fallen due to early detection, improved surgical techniques and 
adjuvant therapy (22). 
 
1.3. Pathology of colorectal cancer 
Colorectal cancer usually develops from normal mucosa to adenoma and then 
progresses to invasive carcinoma (23). Kinzler et al. (24) suggested that approximately 95 
percent of colorectal tumors begin as a benign adenomatous polyp in the wall of the 
colon, developing into advanced adenomas, and then progressing to invasive cancer. The 
progression of this disease involves a series of genomic events, such as alterations in 
several oncogenes, tumor-suppressor and DNA repair genes, cell adhesion molecules, 
angiogenetic factors, and epigenetic factors (18). Colorectal tumors that are confined 
within the wall of the colon (stages I and II) are usually curable, but if left untreated they 
may spread to regional lymph nodes (stage III) or metastasize to distant sites (stage IV) 
(25).  
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1.4. Incidence and risk factors of colorectal cancer 
Colorectal cancer accounts for over 9% of all cancers and as such is a significant 
cause of morbidity and mortality throughout the world (1, 2). Colorectal cancer is the 
third most common cancer worldwide and the fourth most common cause of cancer-
related death (1). The incidence of colorectal cancer is not uniform throughout the world 
(2). Australia, New Zealand, Canada, United States, and parts of Europe are the countries 
with the highest incidence of this disease presumably because of the westernized diet and 
life-style. In contrast, developing countries such as China, India, and parts of Africa and 
South America have lower rates of this disease (2, 21). The incidence in developed 
countries is about 40 per 100,000 compared to five per 100,000 in Africa and some parts 
of Asia (1). 
In Canada, colorectal cancer is the third most common cause of cancer-related 
death and the highest incidence of this disease is observed in NL (3). According to the 
report of the Canadian Cancer Society, it was estimated that approximately 23,900 
Canadian would develop colorectal cancer in 2013 and 9,200 would die of this disease 
(12.7% of all cancer deaths) (3). The current estimated 5-year survival rate in Canada is 
65% (3). 
A number of factors contribute to the cause of colorectal cancer, including 
increasing age, nutritional factors, low physical activity, inflammatory bowel disease and 
genetic risk factors. Environmental risk factors are controllable, unlike hereditary factors 
and age. Evidence for the role of environmental risk factors comes from studies of those 
who migrate to other countries (26, 27). Those migrating from low-risk countries to high-
risk countries have a tendency of having the increased risk of colorectal cancer typical of 
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the host population (26). For example, Japanese who migrate to Hawaii have increased 
risk of colorectal cancer compared with the Japanese who stay in Japan (26). One major 
reason for this is that western diets are high in fat, especially animal fat which is a major 
risk factor for colorectal cancer (2, 26). The EPIC (European Prospective Investigation 
into Cancer and Nutrition) study identified an increased risk of colorectal cancer in 
people with high consumption of meat (27). Other studies linked low folate (28-30) and 
low fiber consumption (31) with a higher risk of colorectal cancer. It is estimated that 
about 80% of all cases of colorectal cancer are caused primarily by diet. Thus changes in 
dietary habits might reduce the risk of this disease substantially (32). 
Several other life-style factors are also associated with increased risk, including 
low levels of physical activity. Regular exercise increases metabolic rate and maximal 
oxygen uptake (33). Epidemiological studies show that men who are physically active 
have decreased risk of developing colorectal cancer (33). Cigarette smoking is another 
risk factor for colorectal cancer. Botteri et al. (34) reported that cigarette smoking is 
linked with formation and increased growth rate of adenomatous polyps which are 
precursor lesions of colorectal cancer. Regular consumption of alcohol may be associated 
with increased risk of colorectal cancer because reactive metabolites of alcohol, such as 
acetaldehyde, can be carcinogenic (35). Supporting this, another report suggested that 
those who are high consumers of alcohol also have diets low in essential nutrients, which 
can make their tissues more susceptible to carcinogenesis (1). 
While dietary and other life-style factors may be controlled to some extent, 
colorectal cancer risk factors that an individual cannot control include age and hereditary 
factors. It is estimated that approximately 1% to 5% of colorectal cancer cases are linked 
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to highly penetrant genetic variants (36), such as the APC mutations in familial 
adenomatous polyposis (FAP), and mutations of DNA mismatch repair genes in Lynch 
syndrome (36, 37). In addition to these high-penetrance mutations, low penetrance alleles 
also contribute to the risk of colorectal cancer (38). The likelihood of developing 
colorectal cancer increases progressively from age 40 and rises sharply after age 50 (1, 
21). More than 90% of colorectal cancer occurs in individuals aged 50 and over (21, 31). 
 
1.5. Sporadic, hereditary and familial colorectal cancer 
 
1.5.1 Sporadic colorectal cancer 
Sporadic colorectal cancer development is multifactorial and is probably due to 
the combinations of numerous low-penetrant alleles and environmental or behavioral risk 
factors (39). In sporadic patients, there is no known familial history of colorectal cancer 
and age of diagnosis is usually late (median ~70 years) (40, 41). Low-penetrant alleles 
contribute modestly to the increase in colorectal cancer risk but when they interact with 
other susceptibility alleles or environmental factors they can modify the risk for colorectal 
cancer (42). Recently, several genome wide association studies (GWASs) have identified 
several single nucleotide polymorphisms (SNPs) that modestly influence the risk of 
colorectal cancer (43). Several meta-analyses have validated some of these genetic 
polymorphisms as susceptibility loci (38, 43, and 44). 
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1.5.2 Hereditary and familial colorectal cancer 
 
A. Polyposis syndromes 
 
Familial Adenomatous Polyposis (FAP) 
FAP is an autosomal dominantly inherited syndrome caused by genetic mutations 
in the adenomatous polyposis coli gene (APC) (45, 46). It is characterized by the 
development of multiple (hundreds to thousands) adenomas in the rectum and colon after 
the first decade of life, resulting in colorectal tumors if not removed (46). Germline 
mutations in the tumor suppressor gene APC on chromosome 5q21 are the causes of FAP 
(47, 48). The APC protein is a part of a protein complex that targets β-catenin for 
degradation via GSK-3β–mediated phosphorylation (49). The median age of diagnosis of 
FAP is about 40 years, or 10 to 15 years after the initial development of polyposis (50, 
51). 
FAP exhibits close to 100% penetrance. More than 90% of patients with FAP will 
develop duodenal, ampullary, or peri-ampullary adenomas and 5% to 10% of the patients 
will develop duodenal carcinoma by the age of 60 (52, 53). A less aggressive but more 
variable variant of FAP is attenuated FAP (AFAP) characterized by fewer colorectal 
adenomatous polyps (usually 10 to 100) which is caused by mutations in the 3' part of 
APC (54). In some families with the mutations in 5’ end of the APC gene, the polyp 
burden is highly variable, from 10-20 polyps to 100s to 1000s polyps (55). Other variants 
of FAP are Gardner syndrome and Turcot syndrome. In Gardner syndrome numerous 
extracolonic features are observed, such as skin tumors, epidermoid cysts, congenital 
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hypertrophy of the retinal epithelium and desmoid tumors (56). This syndrome is also 
caused by mutations in the APC gene and may represent variable expression of a mutation 
also causing classic FAP (56). Turcot syndrome is a rare variant of FAP (57) in which 
patients develop polyposis and colorectal cancer along with central nervous system 
tumors (57). Studies associate Turcot syndrome with mutations in the DNA mismatch 
repair genes, MLH1 and MSH2 (57), and APC (58). 
 
MUTYH-Associated Polyposis (MAP) 
MUTYH-associated polyposis (MAP) is an autosomal recessive disorder 
characterized by adenomatous colon polyps and risk of colorectal cancer (59). It is caused 
by the mutation in the MUTYH gene (59). Patients with this disease typically develop 10–
500 adenomas (59). MAP may account for 0.5% to 1% of all colorectal cancer cases (60). 
The age of onset of MAP has not been fully defined, but based on colorectal cancer 
cohort studies, it was suggested to be between ages 50 and 60 (61). A study by Jenkins et 
al. estimated that the lifetime risk for individuals with biallelic MUTYH-mutations to 
develop colorectal cancer is 80% (62). MUTYH is located on chromosome 1p34 
(www.lovd.nl/MUTYH). It encodes a DNA glycosylase which plays a role in the DNA 
base-excision repair pathway (63). Two common MUTYH variants observed in MAP 
patients are the Tyr165Cys and Gly382Asp mutations (64).  
 
 
 
9 
 
Hyperplastic Polyposis Syndrome (HPPS) 
HPPS is a rare condition that is characterized by the presence of multiple or large 
polyps throughout the colon (65). While it is inherited, no specific germ-line mutations or 
genetic abnormality have been noted in patients with HPPS (66). Individuals with this 
syndrome have a high risk of developing colorectal cancer (65). According to Young et 
al. (67) 50% of individuals with HPPS report a family history of colorectal cancer. 
Colorectal tumors in HPPS often have microsatellite stable (MSS) tumor phenotype 
(where mismatch DNA repair genes are not mutated) (66). Despite the different studies 
carried out, the mode of inheritance has not yet been completely determined, but based on 
the reports by Chow et al. (66) and Young et al. (67), either autosomal recessive or co-
dominant is the most likely mode of inheritance. 
 
B. Hamartomatous polyposis syndromes 
 
Juvenile Polyposis Syndrome (JPS) 
JPS is an inherited, autosomal dominant disorder distinguished by hamartomatous 
polyps in the gastrointestinal tract (68). Patients with JPS are likely to have various 
malignancies such as gastrointestinal, pancreatic, lung, uterine, ovarian and testicular 
tumors (69-71). About 68% of the JPS patients develop colorectal cancer by the age of 60 
and average age of diagnosis of colorectal cancer is 42 (69). JPS is caused by germline 
mutations in the SMAD4/DPC4 gene located on chromosome 18q21.1 and the BMPR1A 
gene located on chromosome 10q22-23 (72, 73). 
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Cowden’s Syndrome (CS) 
CS is another rare, autosomal dominant hamartomatous polyposis condition also 
characterized by tumors of breast, skin and thyroid (74). Germline mutations of PTEN are 
the cause of this disease (74). PTEN is a tumor suppressor gene and encodes a lipid 
phosphatase that regulates the PI3K/AKT pathway (75). Mutations in PTEN cause 
increased nuclear β-catenin that can lead to increased expression of c-Myc and cyclin D1 
(CCND1) (75), two important cell signaling and cell cycle proteins with roles in 
carcinogenesis. 
 
Peutz-Jeghers Syndrome (PJS) 
PJS is an autosomal dominant syndrome leading to the development of 
gastrointestinal hamartomas and mucocutaneous hyper-pigmentation (76, 77). The overall 
incidence of colorectal carcinomas in PJS patients ranges from 20–50% (76, 77). Over 
their lifetime, patients with PJS have a 39% chance of developing colon cancer (76, 77). 
Germ-line mutations in STK11 (LKB1) are the cause of PJS. STK11, a tumor suppressor 
gene located on chromosome 19p13 (76, 77), encodes a serine-threonine kinase that 
modulates cell polarity and cell proliferation (76, 77). 
 
C. Hereditary non-polyposis colon cancer 
Hereditary non-polyposis colorectal cancer (HNPCC) can be sub-divided into two 
categories: Lynch syndrome (LS), which is caused by the DNA mismatch repair (MMR) 
gene mutations; and familial colorectal cancer type X (FCCX). The genetic causes of 
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FCCX is currently unknown (78), but likely there are many different genes mutated in 
different families. 
LS is an autosomal dominant condition that is responsible for 2% to 5% of all 
colorectal carcinoma cases (78, 79). Lynch syndrome is caused by germline mutations in 
one of the several MMR genes such as MSH2, MLH1, MSH6 and PMS2 (80-88). These 
MMR genes encode proteins that help maintain the integrity of short segments of 
nucleotide repeats known as microsatellite sequences (80-88). When MMR genes are 
mutated, the encoded proteins are unable to repair bases that are incorrectly added to or 
deleted from microsatellite sequences during DNA replication (88). Thus, colorectal 
tumours in LS patients are characterized by microsatellite instability (MSI) (89). MMR 
mutation carries have a 50–80% lifetime risk of developing colorectal cancer, 50–60% 
risk of developing endometrium carcinoma (in women), and up to 15% risk of other 
tumors such as tumors of stomach, ovary, hepatobiliary tract, upper urinary tract, 
pancreas, small bowel and central nervous system (78). Abdel-Rahman et al. (78) 
reported that the median age of colorectal cancer diagnosis in Lynch syndrome patients is 
44. 
FCCX patients meet the Amsterdam criteria I (briefly, early age of diagnosis and 
multiple individuals affected in more than one generation) but show no evidence of MMR 
gene defect (90). Patients with FCCX have increased risk of colon cancer, but usually not 
of the other cancers that are typical of Lynch syndrome (90). The average age of onset is 
about 60 years, which is higher than in LS (90). In spite of intensive research, the genes 
for FCCX have so far remained unidentified (78). It is also possible that some or many 
cases of FCCX are due to clustering of sporadic colorectal cancer. 
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1.6. Prognostic markers in colorectal cancer 
According to the definition by the National Cancer Institute, “prognosis is an 
estimate of the likely course and outcome of a disease” (31). There are increasing 
numbers of prognostic factors that have been identified over the years, some of which 
may be used in outcome predictions and management decisions. Prognostic factors that 
have been repeatedly investigated include stage, age at diagnosis, residual disease, 
histologic type and grade, carcino-embryonic antigen (CEA) levels, extramural venous 
invasion, and submucosal vascular invasion in malignant polyps (6). Many molecular, 
protein, and carbohydrate markers have been investigated as possible prognostic factors, 
but so far none has been integrated into patient care (6).  
In 1999, the College of American Pathologists (CAP) evaluated the prognostic 
roles of pathologic, genetic, molecular, and other biological factors in colorectal cancer 
(6). Putative prognostic factors were grouped into categories that reflected the strength of 
the published evidence demonstrating their prognostic value (6).  
 
1.6.1 Category I: prognostic markers used for management of colorectal cancer 
patients 
Category I markers were defined by CAP as the best indicators of prognosis for 
colorectal cancer and include tumor stage, regional node involvement, vascular invasion, 
and residual tumor (6). This group of prognostic factors are those that are well 
documented with evidence from multiple published and statistically robust trials and are 
used clinically (6).  
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Tumor stage (defined based on the tumor characteristics) and disease stage 
(defined based on both the tumor characteristics and the presence or absence of 
metastases detected by diagnostic imaging) are well-established prognostic markers used 
in the clinic; they indicate the extent of the disease (i.e. size of the tumor, the depth of 
tumor penetration or metastatic disease) and influences survival outcomes of patients (91-
93). Survival in colorectal cancer is highly dependent upon the stage of the disease at 
diagnosis. The 5-year survival rates are about 90% for stage I (early stage), 70% for 
regional tumors (stage II and III) and 10% for people diagnosed with distant metastatic 
cancer (stage IV) (94). Accurate staging is very critical for appropriate patient 
management and meaningful clinical research (95). Although a large number of staging 
systems have been developed for colorectal cancer over the years, only the TNM 
(Primary tumor-T, Regional lymph node-N, and Distant metastasis-M) staging system of 
American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (IUAC) is widely recommended (96, 97). 
Regional node involvement, which is a part of the TNM staging, is a strong 
predictor of outcome in colorectal cancer (6). TNM classifies nodal involvement as a 
prognostic marker in colorectal cancer based on the number of cancer-invaded lymph 
nodes (96, 97). Reports show that the number of lymph nodes obtained during surgery is 
critical for the prognosis of stage II and stage III colon cancer patients (98, 99) as it helps 
with accurate TNM staging. Expert groups recommend at least 12 nodes be examined 
histologically to accurately determine the nodal status (6, 100). 
Another important prognostic determinant in colorectal cancer is the lymphatic or 
vascular invasion. In these cases, tumor invasion occurs in veins or in small non-
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muscularized vessels that represent either post-capillary lymphatics or venules (6). 
Invasion of tumor cells into lymph or blood vessels is a (crucial) step in the metastatic 
process (101). Lymph node metastases and distant metastases are common in advanced 
colorectal cancers (102-105). Several studies suggest that venous invasion and lymphatic 
invasion may be independent prognostic factors in colorectal cancer (106-108). 
The amount of residual tumor is a prognostic factor (6). IUIC (109) and AJCC 
(110) classify residual tumor (R) as: R0, no residual tumor; R1, microscopic residual 
tumor; and R2: macroscopic residual tumor. The better the original tumor is removed 
during the surgery (e.g. R0), the lower the recurrence risk. 
In essence, the recommendations made by CAP regarding the prognostic factors 
are the best opinion. However, despite the enormous number of studies exploring the 
prognostic significance of various histologic, molecular, and clinical features, clinical 
stage at diagnosis remains the best indicator of the prognosis for colorectal cancer. 
 
1.6.2 Category IIA and IIB: prognostic markers with good evidence but not in use 
for clinical management of colorectal cancer patients 
Based on the CAP guidelines on prognostic factors in colorectal cancer, category 
IIA markers are potential prognostic markers with good evidence but their importance for 
clinical use is not yet established. Such markers include histologic tumor type, tumor 
grade, and MSI status (6). 
Based on previous studies, the signet-ring cell type of adenocarcinoma and small-
cell carcinoma are the only histologic types of colonic carcinoma that consistently have 
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been found to have stage-independent adverse effects on prognosis (111). However, 
usually the establishment of prognostic value of histologic type is hampered by the 
insufficient amount of data extracted during the pathological examination of tumor tissues 
(6). 
Tumor grade is another prognostic marker with strong evidence but not in use in 
the clinic (6). Tumor grade is the degree of tumor differentiation and in some studies has 
been demonstrated to be a stage-independent prognostic factor in colorectal cancer (112). 
In the majority of the studies, the prognostic significance of grade is investigated in 
statistical analysis as low grade (well and moderately differentiated) versus high grade 
(poorly differentiated or undifferentiated) (6). CAP and AJCC/UICC recommended the 
adoption of this two-tiered grading system for colorectal cancer (6, 96, and 97). However, 
despite the number of grading systems that have been suggested in the literature, there is 
no single widely accepted and employed standard for tumor grading (113, 114).  
Last but not least, MSI is considered as a category II prognostic marker for 
colorectal cancer (6). There are three types of MSI tumor phenotype; MSI-H (MSI-high), 
MSI-L (MSI-low), and MSS (microsatellite-stable). Studies show that patients with MSI-
H tumor phenotype have better prognosis when compared to patients with MSS and MSI-
L tumor phenotypes (115).  
 
1.6.3 Category III: genetic markers as potential prognostic markers in colorectal 
cancer 
Many genetic and molecular markers have been identified as having potential 
prognostic or predictive utility for colorectal cancer (6). These potential markers are those 
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listed by CAP under the category III include molecular markers, markers of cell 
proliferation or angiogenesis, and proteases (6). Large prospective cooperative group 
studies are currently ongoing that will clarify the prognostic value of many of these 
factors (6). Table 1.1 shows some of the potential prognostic and predictive genetic 
markers studied in colorectal cancer (6). Below, some of the well-studied markers are 
discussed in detail. 
 
KRAS 
KRAS is a member of the RAS oncogene family (116-118). Mutation of KRAS 
occurs in approximately 50% of colorectal tumors (119). KRAS mutation occurs during 
adenoma progression, after APC mutation (120). Some KRAS mutations are predictive of 
a worse outcome and are associated with recurrence of colorectal cancer after therapy 
(121). However, other studies have failed to demonstrate any statistically significant link 
between KRAS mutations and prognosis (122). Several large studies have also failed to 
demonstrate the effect of KRAS mutations on disease-free or overall survivals, either in 
isolation or in combination with other mutations (123). 
 
TP53 
The TP53 gene is located on the short arm of chromosome 17 (17p13.1) (124). 
The function of TP53 includes control of the cell cycle, DNA repair and synthesis, 
genomic plasticity and programmed cell death (124). That is why it is called the ‘guardian 
of the genome’ (125). 
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Table 1.1: Potential prognostic and predictive genetic markers in colorectal cancer 
(6) 
 
Candidate Biomarkers 
KRAS 
TP53 
DCC/18q 
NM23 
APC 
SMAD4 
BRAF 
MLH1 
TYMS 
TIMP 
VEGF 
CD44 
Matrix metalloproteinases (MMPs) 
BCL-2 
BAX 
TYMP 
MSI 
CEA levels 
C-reactive protein levels 
 
 
TP53 mutations are the most common genetic alterations reported in human 
cancers (126). In colorectal adenomas, TP53 mutations or allelic loss occur as late events 
in tumor progression (127). There are studies suggesting the prognostic and predictive 
significance of TP53 mutations in colorectal cancer. For example, Tortola et al. (128) 
showed that mutations in TP53 were predictive of worse outcome. Yamaguchi et al. (129) 
concluded that patients with TP53 mutated tumors had a five-fold higher recurrence rate 
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and risk of death. However, despite these results, many other studies have failed to 
identify the prognostic effect of TP53 in colorectal cancer. For example, Soong and 
coworkers studied 995 patients with Dukes’ B and C colorectal cancer tumors, and no 
prognostic significance of the TP53 mutations was observed (130). Similarly, the study 
reported by Elsaleh et al. (131) failed to identify an effect of TP53 mutations on 
prognosis or therapeutic response to adjuvant chemotherapy in patients with Dukes’ C 
tumors. Therefore, currently there is no convincing evidence of the prognostic role of 
TP53 mutations in colorectal cancer. 
 
DCC/18q 
DCC (deleted in colorectal cancer) is a gene located on the long arm of 
chromosome 18 (18q) (132). Cytogenetic studies demonstrated that deletions of 
chromosome 18q were relatively common in colorectal cancer (133). In some studies, 
DCC/18q deletion was suggested as a useful prognostic marker (134). However, other 
studies using similar techniques have failed to confirm the prognostic association of loss 
of DCC in patients with colorectal cancer (135). 
 
NM23  
NM23 genes are located on chromosome 17 (17q21.3) and two of these genes are 
found in humans, namely NM23-H1 and NM23-H2 (136). NM23 genes are putative 
metastatic suppressor genes (136). In advanced cases of colorectal carcinoma, somatic 
deletions of the NM23 genes have been reported. Campo et al. (137) identified the 
deletions of NM23-H1 in 56 patients with aggressive behavior of colorectal carcinomas. 
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Similar findings have also been reported by others, showing that over-expression of 
NM23-H1 is significantly reduced in patients with advanced disease compared with 
patients with earlier disease stages (138). However, many other studies have failed to 
demonstrate a prognostic role of NM23-H1 expression in colorectal cancer (139). 
 
1.7. Angiogenesis, lymph-angiogenesis and metastasis 
Angiogenesis is the formation of new blood vessels from an existing blood vessel 
(7). Events included in this process are proliferation, migration, and invasion of 
endothelial cells, organization of endothelial cells into functional tubular structures, 
maturation of vessels, and vessel regression (7). Tumor cells cannot grow beyond a 
critical size or metastasize to another organ without the formation of new blood vessels 
around the cells (7).  
Angiogenesis around tumors was observed many years ago (7, 140). In 1971, 
Folkman proposed that tumor growth and metastasis are angiogenesis-dependent, and that 
if angiogenesis is blocked, then that could help arrest tumor growth (7). Since then, 
intensive search has been done for pro- and anti-angiogenic molecules. Research 
published by Gullino in 1976 showed that cells in pre-cancerous tissue acquire angiogenic 
capacity on their way to becoming cancerous (141). It is now a widely accepted concept 
that angiogenesis is “on” when pro-angiogenic molecules are activated and is “off” when 
they are inhibited (142). Signals that trigger this switch have been discovered by research 
involving hypoglycaemia, mechanical stress generated by proliferating cells, 
immune/inflammatory response (i.e. immune/inflammatory cells that infiltrate the tumor) 
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and genetic mutations that lead to the activation of oncogenes or inactivation of tumour-
suppressor genes that control production of angiogenesis regulators (142, 143). 
Angiogenesis is regulated by many growth factors such as vascular endothelial growth 
factors (VEGFs), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), 
transforming growth factor (TGF), angiopoietins (Angs), and several chemokines (144, 
145). Among these, VEGFs have a predominant role as the key regulators of angiogenesis 
(146). The interaction of the VEGFs and placental growth factor (PGF) family members 
with cell surface receptors (VEGFRs) leads to cascades of signaling that lead to the 
formation of new blood and lymphatic vessels (147) (Figure 1. 1). 
Lymph-angiogenesis is the growth of new lymphatic vessels from an existing 
lymphatic vessel (8). Lymph nodes play an essential role in both normal and pathologic 
conditions (10, 148). In brief, under normal conditions the main functions of the lymph 
nodes are to remove excess fluid from the blood circulation, to transport immune cells 
that help trap infectious agents, and in cancer, to carry cancer cells to the lymphoid 
tissues and beyond (10). However, in cancer various studies show that most human 
tumors are able to metastasize via the lymphatic or blood vessels to other tissues in the 
body (149, 150). 
Expression of lymph-angiogenesis-inducing growth factors in a range of animal 
tumor models has been well studied (151, 152). The signaling system consisting of 
VEGFC and VEGFD binding to VEGFR3 is a well-known mechanism of action behind 
lymph-angiogenesis (148) (Figure 1. 1).  
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Figure 1.1: Interactions between the VEGF ligands and their receptors (VEGFRs) (147, 
148, and 153).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VEGF receptors (VEGFR1, VEGFR2, and VEGFR3) are shown as vertical rectangles. Copyright 
permission by the publisher, Elsevier, of the journal “Current Opinion in Cell Biology”. 
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Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGFRs) 
VEGF ligands and their receptors bind together to activate cellular signals for 
angiogenesis and lymph-angiogenesis. VEGF ligands and receptors are the most intensely 
investigated proteins in cancer as they play crucial roles in both normal and pathologic 
angiogenesis and lymph-angiogenesis (153, 154). The VEGF family of ligands are 
VEGFA, VEGFB, VEGFC, VEGFD and PGF and the three VEGF receptors are 
VEGFR1, VEGFR2 and VEGFR3 (Figure 1.1) (153). VEGFs are up-regulated by 
hypoxia-inducible factor 1α (HIF1α), and extracellular matrix (ECM) for the purpose of 
initiating an angiogenic switch that promotes tumor growth (153). 
Among the VEGF ligands, VEGFA is the most well characterized one (153). The 
mechanism behind the biological effect of VEGFA involves its interaction with the cell 
surface receptors VEGFR1 and VEGFR2 located on the vascular endothelium (153) 
(Figure 1.1). Their interactions play a crucial role in angiogenesis, which is critical for 
cancer progression (153). For example, in breast cancer, increased production of VEGFA 
is correlated with early relapse (155). 
VEGFB is one of the least characterized members of the VEGF family of ligands. 
It was discovered a few years after VEGFA and PGF (156). VEGFB exists in two 
isoforms, which bind to VEGFR1 but not to VEGFR2 or VEGFR3 (Figure 1.1) (157). It 
is expressed in the endothelial and mural cells, skeletal muscle, adipose tissue, and 
smooth muscle cells in adults (156, 158). According to studies, VEGFB is detectable in 
many tumors including colorectal, meningioma, lung and breast tumors (159-161).
 
VEGFC is another VEGF ligand. VEGFC binds to VEGFR2 and VEGFR3 
(Figure 1.1) (162). The VEGFC signaling via VEGFR2 and VEGFR3 plays a critical role 
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in cancer progression (163). Mandriota et al. (164) showed that VEGFC is involved in 
tumor lymph-angiogenesis through inducing the formation of additional lymphatic 
vessels by which tumors cells find a channel to metastasize to distant sites. Further 
reports show that VEGFC is involved in the progression of several types of malignant 
tumors such as lung, colorectal, and breast tumors (165-167). 
VEGFD is another ligand of the VEGF family. It stimulates the growth of 
vascular and lymphatic endothelial cells by signaling via VEGFR2 and VEGFR3 (168) 
(Figure 1.1). VEGFD is expressed in the adult lung, heart, muscle, and small intestine, 
but mostly found in the foetal lungs and skin (168). Expression of VEGFD in many tumor 
types has been detected, and it has been implicated to have a role in tumor angiogenesis 
and lymph-angiogenesis in breast cancer (169), esophageal squamous cell carcinoma 
(170), and lung cancer (171). Expression of VEGFD has also been implicated as a poor 
prognostic marker for colorectal (172), ovarian (173), gastric (174), and lung cancers 
(175).  
PGF, placental growth factor, is another VEGF ligand (176). It is expressed in the 
placenta, heart and lungs (177). So far, four human PGF isoforms have been reported 
(178). PGF binds to the cell surface receptor VEGFR1 located on the vascular 
endothelium, which can stimulate angiogenesis (179) (Figure 1.1). It helps in the growth, 
migration and survival of the endothelial cells (178, 179). A report by Fischer and 
coworkers showed that PGF is involved in various pathological conditions such as tumor 
growth, arthritis, ocular ischaemia, and obesity (180). Wei et al. (181) linked PGF 
expression with disease progression in colorectal cancer. The Chen et al. (182) report 
correlates tumor stage and patient survival in gastric cancer. Also, elevated levels of PGF 
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expression were associated with recurrence, metastasis and patient mortality in breast 
cancer (183). 
VEGFR1, also known as FLT1, is a cell surface receptor expressed at high levels 
in the vascular endothelial cells throughout fetal development and in the adult tissues 
(180, 184). It is activated when VEGFA, VEGFB or PGF binds to it (180, 184) (Figure 
1.1). VEGFR1 helps the migration of the endothelial cells (180). VEGFR1 has been 
found to be expressed in various types of malignant cells such as colorectal, prostate, 
breast, esophageal cancers and leukemia (185-188). 
VEGFR2, also known as KDR in humans, is a cell surface receptor that plays a 
very important role in the development of endothelial cells (189). It is expressed in the 
vascular endothelial cells located on the vascular endothelium (189). VEGFR2 can be 
activated when VEGFC or VEGFD ligands bind to it (189) (Figure 1.1). Shibuya 
describes VEGFR2 as a major inducer of angiogenesis as it helps promote endothelial cell 
differentiation, proliferation, migration and formation of new vascular vessels (190). 
VEGFR2 is implicated as a prognostic marker in patients with different types of 
malignancies including endometrial carcinoma and colorectal cancer (191, 192). 
VEGFR3 is also a cell surface receptor located on the vascular endothelium. It is 
coded by the FLT4 gene in humans. VEGR3 is activated when VEGFC or VEGFD 
ligands bind to it (162, 168) (Figure 1.1). Its major function is to induce lymphatic 
endothelial cells to form new lymphatic vessels (162, 168). According to literature 
findings, the interaction of VEGFC and VEGFR3 plays a role in disease progression and 
lymph node metastasis in prostate cancer (193). Other studies have also reported 
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VEGFR3 as involved in the progression of several types of malignant tumors, such as 
colorectal, breast, and melanoma tumors (192, 194 and 195). 
Metastasis is the spread of cancer cells from the primary tumor site to the lymph 
nodes or to other tissues in the body (e.g. liver, brain). Abnormalities in tumor 
angiogenesis and lymph-angiogenesis are the key causes of this often deadly problem (10, 
140 and 147). Studies suggested that the spread of primary tumor cells to distant organs 
depends critically on the formation of new blood vessels and lymphatic vessels, because 
these vessels not only provide oxygen and nutrients, remove waste materials from the 
tumor but, also provide a route of exit for tumor cells into the blood stream or lymph 
nodes (145, 147). 
The most convincing correlation between angiogenesis and tumor metastasis has 
been reported in cases where vascular density of tumors has been correlated with 
metastasis and patient outcome. Weidner et al. (196) showed a direct correlation between 
the vascular density and the risk of metastasis in breast cancer patients. Other groups have 
repeated this study and most have confirmed the initial correlation not only in breast 
cancer but also in tumors of other tissues such as prostate, lung, stomach, and cervix 
(196-200).  
For tumor cells to metastasize, they must detach themselves from the tumor. The 
degradation of the extracellular matrix (ECM) plays a critical role in this process (201). 
Many reports show that one of the hallmarks of cancer cells is the alteration of their 
interactions with the ECM, which is induced either by the tumor cells or by surrounding 
cells such as fibroblasts, macrophages and leukocytes (201). The ECM can regulate tumor 
cell growth by binding to and storing cytokines, by promoting cell attachment and 
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migration, by providing a stable foundation, supporting cell growth and survival by 
interacting with cell-surface receptors, and by activating appropriate signaling pathways 
(202, 203). According to Chambers and Matrisian, matrix metalloproteinases (MMPs) are 
implicated in the progression of many human cancer types because they help the 
degradation of the ECM, thus helping cancer cells to spread to distant organs which are 
the main cause of death in patients with malignant disease (204).  
According to the HUGO database (205), there are 23 MMP genes in the human 
genome. Several studies investigated the roles of MMPs in cancer progression. For 
example, one study showed that high serum levels of MMP9 was associated with rapid 
progression, poor survival and secondary metastasis in patients with melanoma (206). In 
other studies, lymph node metastases and poor outcome was associated with the tumor 
levels of MMP9 and MMP2 in patients with laryngeal cancer (207, 208). In summary, 
these and previously discussed literature findings suggest that in addition to VEGFs and 
VEGFRs, MMPs may also play crucial roles in cancer progression. 
 
1.8. Angiogenesis, lymph-angiogenesis and metastasis pathways and prognosis in 
colorectal cancer 
The connection between the genes functioning in angiogenesis, lymph-
angiogenesis, and metastasis processes and prognosis in colorectal cancer has been 
investigated intensively over the years. The majority of these studies focused on VEGFA. 
For example, high levels of VEGFA expression in metastatic human colon carcinomas 
have been reported to correlate with poor prognosis in patients (209). In another report, 
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VEGFA expression was found to be higher in metastatic tumors than in non-metastatic 
tumors, and was correlated with liver metastasis and poor patient prognosis (210). 
Takahashi et al. (211) showed that colon cancer patients with tumors with increased 
VEGFA levels have significantly shorter 5-year disease-free survival (DFS) times. 
Cascinu et al. (212) confirmed this finding. Another study reported the relation of high 
VEGFA expression with progression in colorectal cancer where a greater intensity of 
VEGFA staining was associated with greater lymph node metastasis, higher stage, and 
shorter disease-specific survival; based on these results the authors concluded that 
VEGFA expression in colorectal cancer appears to be an independent prognostic marker 
of tumor behavior and can be useful in identifying patients with unfavourable clinical 
outcome (213). 
Other studies reported the prognostic significance of the serum VEGFA levels in 
colorectal cancer. An example of this was a large study conducted by the Danish 
Colorectal Cancer Study Group (214) where high preoperative VEGFA concentrations 
were associated with reduced overall survival times in patients with colon carcinoma 
(214). In addition, De Vita et al. (215) reported that preoperative serum VEGFA level 
might be useful for predicting outcome in patients with colon cancer who undergo 
surgery. 
Although not intensely studied, other VEGF family ligands have also been 
reported to be associated with the progression of colorectal cancer. In one study, PGF 
levels were reported to be associated with disease progression and patient survival in 
colorectal cancer (216). Jayasinghe et al. (217) reported that VEGFB promotes tumor 
survival and thus helps progression of colorectal cancer while White et al. (218) reported 
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that the expression of VEGFD was associated with lymphatic involvement and reduced 
patient survival in colorectal carcinoma. Also, Rmali et al. (219) reported a correlation of 
VEGFR2 expression with disease progression in colorectal cancer patients. 
The matrix metalloproteinases (MMPs) have also been implicated in the 
progression of colorectal cancer. Several studies reported over-expression of MMP1, 
MMP2, MMP3, MMP7, MMP9, and MMP13 in colorectal tumors (220). One report 
showed that high levels of MMP3 expression in colorectal cancer were associated with 
poor prognosis (221). Further, a meta-analysis highlights the prognostic effect of MMP9 
in colorectal cancer patients; in this analysis patients with higher tumor expression of 
MMP9 were found to have poorer survival (222). Another study, including a meta-
analysis suggested that tumor MMP2 expression is an independent prognostic factor in 
colorectal cancer patients (223; 224). Yang et al. (225) reported that over-expression of 
MMP12 can predict outcome in patients with colorectal cancer. These and other literature 
findings suggest a critical role of VEGFs, VEGFRs and MMPs in prognosis and 
progression of colorectal cancer. 
 
1.9. Genetic polymorphisms in angiogenesis, lymph-angiogenesis and metastasis 
pathway genes and their relation to progression in colorectal cancer 
A number of studies analyzed genetic polymorphisms in VEGF ligand and 
receptor genes and MMP genes in relation to the prognosis of colorectal cancer patients. 
The majority of these studies are summarized in the public dbCPCO database (database 
of colorectal cancer prognosis and clinical outcome) (226). 
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According to the dbCPCO database, a number of VEGFA polymorphisms have 
been examined in different studies, but often reported conflicting results. As an example, 
Dassoulas et al. (227) reported that one VEGFA SNP (-634G/C; NM_001025366.1:c.-
94C>G) was associated with overall survival (OS) in colorectal cancer patients. However, 
many other studies did not find this association in their cohorts (228-232). Similarly, 
Zhang et al. (233) showed no association of another VEGFA SNP (+936C/T; 
NM_001025366.1:c.*237C>T) with OS or DFS, yet Dassoulas et al. (227) reported an 
association of this polymorphism with prognosis. For another VEGFA SNP (-1498C T/C 
in promoter; NG_008732.1:g.4534C>T), associations with OS and DFS in stage II 
patients and progression free survival (PFS) and OS in metastatic colorectal patients was 
reported (234), however other groups did not replicate these findings (232, 235). In the 
case of the -2578C/A polymorphism (NG_008732.1:g.3437A>C), no association was 
detected with OS and DFS (231) or with PFS in colorectal cancer patients (232). As of 
October 2013, there were no entries in the dbCPCO database regarding polymorphisms in 
other VEGF ligand genes and prognosis in colorectal cancer. 
Among the VEGFRs, KDR is frequently studied in prognostic studies in 
colorectal cancer. Hansen et al. (236) investigated the prognostic effect of a KDR 
polymorphism (-604 T/C; NM_002253.2:c.-906T>C) and reported its association with 
PFS in a cohort of colorectal cancer patients, but conflicting results regarding this 
polymorphism were also reported (232, 237 and 237). In addition, association of another 
KDR SNP (1719 A/T; NP_002244.1:p.Gln472His), with survival was identified in 
multiple studies (236, 237). Lastly, one study that analyzed the prognostic effect of the 
VEGFR1-519C/T genetic variation did not find association with patient survival (238). 
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According to the dbCPCO database, a small number of studies were conducted 
investigating the polymorphisms from the MMP genes and the survival outcomes in 
colorectal cancer. Hettiaratchi et al. (239) reported that one MMP1 polymorphism (-1607 
indelG in the promoter; NM_001145938.1:c.-1719delG) was associated with better OS, 
but this was not replicated in other studies (240-242). Langers et al. (243) reported the -
1306C/T MMP2 polymorphism; NG_008989.1:g.3726C>T) to be associated with better 
OS in colorectal cancer patients, which was not detected in a number of other studies 
(244, 245). 
Based on both the small number of studies and polymorphisms investigated, as 
well as the conflicting results reported in literature, it can be concluded that the potential 
associations of VEGF, VEGFR and MMP polymorphisms with colorectal cancer patient 
prognosis is neither well-established nor well-studied.  
 
1.10. SNP-based and haplotype-based genetic association studies 
The human genome contains many sequence variations. These genetic variations 
include single nucleotide polymorphisms (SNPs), insertion/deletion of one or more 
nucleotides (indels), and microsatellite repeats (246). Of these, SNPs are the most 
frequent, with an estimated number of more than eleven million (246). SNPs occur within 
both coding and non-coding regions of genes and within intergenic regions. The SNPs in 
or close to genes can have functional consequences, such as changing amino acid 
sequences, affecting mRNA stability or altering gene expression levels (247). 
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Some of the variants in human DNA are the causes of the differences in 
phenotype and disease risks (246). There has been a major interest in identifying the 
genetic variations that can affect susceptibility to common diseases, and response to 
medical treatment (248-250). Thousands of GWAS have been published, some of which 
have identified common genetic variants conferring risk to specific diseases. For 
example, almost 4,000 SNP associations have been identified in ~200 diseases and traits 
(251). In these studies, usually the association of individual SNPs with the disease risk 
have been tested (SNP-based association studies). 
Many researchers have suggested that haplotype analysis may provide additional 
information (252). Haplotypes are the combinations of alleles at different genomic loci. In 
some cases, haplotype analysis maybe more powerful than a SNP analysis, because the 
combination of several genetic variations may be associated with the phenotype (253-
257). For a given genomic region on autosomal chromosomes, each individual inherits 
two sets of haplotypes, one from each parent (258). The commonly used haplotype 
phasing software include Arlequin (259, 260), PHASE II (261, 262), and Haplotyper 
(263). These applications can be used to predict the phased haplotypes of an individual by 
assigning the best possible combination of paired haplotypes based on the genotype data 
(261-263). The disadvantage of these statistical packages is that their results are not 
always accurate because a proportion of the inferred haplotypes may be incorrect (261-
263). This is because it is often impossible to be certain about the haplotypes carried by 
one individual unless a family analysis is done (261-263). 
While the genetic prognostic studies that test the association of genetic variations 
with survival outcomes of cancer patients is a relatively new field, both SNP-based and 
32 
 
haplotype-based association studies have been performed in colorectal cancer (14, 15). 
SNP-based and haplotype-based analyses can be complementary approaches in 
identifying the prognostic associations of genetic variations and genes in cancer. 
 
1.11. Rationale, hypothesis and specific objectives of the research project 
 
Rationale and hypothesis 
Extensive biological and clinical findings suggest that abnormalities in 
angiogenesis, lymph-angiogenesis and metastasis may affect tumor progression and 
patient survival. Despite this strong evidence, the genetic basis of this relationship 
remains poorly characterized. In this study, I hypothesize that genetic alleles and their 
combinations as haplotypes from select genes acting in the angiogenesis, lymph-
angiogenesis, and metastasis pathways are associated with clinical outcome in colorectal 
cancer patients. 
 
Specific objectives 
The overall aim of this research study is to identify new candidate markers that, 
once validated, may be used to improve prognostic accuracy in colorectal cancer patients. 
The specific objectives of this study are: 
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1. To investigate the associations between 381 individual genetic variants within 30 
angiogenesis, lymph-angiogenesis and metastasis genes and outcome in a cohort 
of 505 colorectal cancer patients from NL. 
2. To investigate the associations of haplotypes for these genes with outcome in the 
same patient cohort.  
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Chapter 2: Patient Cohort and Methodology 
 
2.1. Ethics approval 
This study was approved by the Health Research Ethics Board of Newfoundland 
(HREB Reference # 12.206). 
 
2.2. Credits and collaborations 
Lydia A. Dan: prepared the bfile to be used by the PLINK software to extract the 
genotypes and other related information for polymorphisms investigated in the study 
cohort; performed statistical analysis on the clinicopathological and treatment-related 
features and the 381 polymorphisms described in this thesis document; ran the PHASE II 
program together with Salem Werdyani using the input files prepared by Salem 
Werdyani; organized and interpreted the results with the help of the thesis supervisor; 
prepared the linkage disequilibrium map of the MMP8-MMP27 genomic region; 
performed literature searches in order to interpret and discuss the results as described in 
this thesis document. 
Salem Werdyani: prepared the input files for the PHASE II program and ran PHASE II 
to predict the haplotypes; involved in the preparation of the bfile to be used by the PLINK 
software to extract SNP genotypes and other relevant information. 
Jingxiong Xu: from Princess Margaret Hospital, Toronto, Ontario; helped to perform 
quality control and population structure analyses based on the genotype data of the patient 
cohort. 
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Konstantin Shestopaloff: from University of Toronto, Ontario; contributed to the quality 
control and population structure analyses based on the genotype data of the patient cohort. 
Dr. Patrick Parfrey: provided the genetic, clinicopathological and prognostic data used 
in this analysis.  
Dr. Roger Green: provided the genetic, clinicopathological and prognostic data used in 
this analysis.  
Dr. Wei Xu: from Princess Margaret Hospital, Toronto, Ontario; led the quality control 
and population structure analyses based on the genotype data of the patient cohort; helped 
with the study design, haplotype and statistical analyses and interpretation of the results. 
Dr. Sevtap Savas: processed and coded the prognostic data for the patient cohort used in 
this study; combined the coded prognostic data with the coded genotype data for 
statistical analyses; provided the baseline characteristics tables as well as the statistical 
results on comparison of the NFCCR cohort (n=736) and the patient cohort investigated 
in this study (n=505); designed and led the project and supervised the thesis author 
throughout her program. 
NFCCR Investigators: many investigators and personnel including Dr. Jane Green and 
Dr. Betty Dicks have contributed to the data collected and patients recruited to NFCCR. I 
gratefully acknowledge their contributions to this project. 
 
Funding agencies 
This study was supported by funds by the Canadian Institutes of Health Research 
(CIHR), Research and Development Corporation of Newfoundland (RDC), and the 
Medical Research Foundation (MRF) of Faculty of Medicine, Memorial University. 
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2.3. Patient cohort 
A sub-cohort of patients recruited to the Newfoundland Colorectal Cancer 
Registry (NFCCR) was investigated in this study. The NFCCR was established in 1999 
(264). Patients were eligible to join the NFCCR if they were diagnosed with colorectal 
carcinomas between 1 January 1999 and 31 December 2003 and were under 75 years of 
age. Informed consent was obtained from either the patients or their family proxies. In 
this cohort, there are 736 stage I-IV patients. These patients were followed up by the 
NFCCR until 2010. Collection of the prognostic data was described previously (265). Of 
these 736 patients, clinicopathological and prognostic data and DNA samples extracted 
from blood were available for 539 patients. These 539 patients were genotyped as 
described in Section 2.4. Out of 539, 505 patients were selected to be included in this 
study as described in Section 2.5. 
The NFCCR also provided patient and disease related variables including age at 
diagnosis, sex, disease stage, tumor grade, vascular and lymphatic invasion status, tumor 
histology, MSI status, tumor location, familial risk status, BRAF-Val600Glu mutation 
status, adjuvant chemotherapy, adjuvant 5-Fluorouracil (FU)-based chemotherapy, and 
adjuvant radiotherapy status. Familial risk status was determined by NFCCR investigators 
using the Amsterdam and Bethesda criteria based on the patient family history as 
described in Green et al. (264). The MSI and BRAF-Val600Glu mutation status of the 
tumors were determined as described in Woods et al. (266). 
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2.4. Genotyping 
Genomic DNA from 539 colorectal cancer patients (for whom prognostic data 
were available) was genotyped using the Illumina® human Omni1-Quad genome-wide 
SNP genotyping platform in an outsourced genomic facility (Centrillion Bioscience, 
USA). The chip used is designed based on tagSNP (i.e. tagging SNP) data and contains 
1,134,514 SNP probes. The genomic coverage rate is about 93% and the median distance 
between the SNPs is 2.6 kb (267). Approximately 123,000 SNPs failed to be genotyped in 
this genotyping experiment. The genotypes of the remaining SNPs were recorded in a 
bfile (binary data file) by the outsourced genomics facility (Centrillion Bioscience, USA). 
 
2.5. Quality control measures and inclusion-exclusion criteria for patients and 
genotype data 
Quality control measures and inclusion-exclusion criteria were implemented on 
the data of 539 patients in order to have an ethnically homogenous population that 
consists of patients with high-quality genotype data. The following analyses were 
performed by Jingxiong Xu, Konstantin Shestopaloff and Dr. Wei Xu at the University of 
Toronto and the Princess Margaret Hospital, Toronto, Ontario. 1) Using the X-
chromosome heterozygosity rate analysis, one sample was excluded from further analysis 
because the gender information indicated by the genetic data did not match the recorded 
gender of the patient. 2) The data was checked for individuals with a high missing 
genotype rate (>5%), but none of the patients failed this condition (i.e. all patients had 
>95% genotype call rates). 3) The data was checked for duplicate DNA samples but no 
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accidentally duplicated sample in the patient cohort was identified. 4) Among the 539 
patients, 1
st
, 2
nd
 and 3
rd
 degree relatives who share similar genetic profiles were checked 
using the Identity by Descent method (268). As a result, a total of 21 patients (based on 
PI-Hat score threshold of >0.13) were excluded from our analysis. 5) Individuals with the 
outlying heterozygosity rate were identified using the mean heterozygosity rate 
information for each patient. As a result, one patient was excluded. 6) The patients’ 
ethnicities were estimated with two statistical methods; multidimensional scaling (MDS; 
269), and Principal Component Analysis (PCA; 270, 271). The public HapMap III 
Caucasian population data was used as a reference for the MDS analysis. As a result of 
these analyses, 11 samples were identified as population outliers (i.e. non-Caucasians). 
After this filtering, 505 patients met the quality control and inclusion-exclusion criteria 
and were included in the analysis. Table 2.1 shows the baseline characteristics of the 505 
colorectal cancer patients that constituted the study cohort. 
 
2.6. Genes selected for this project 
By literature search, 31 genes were identified that play biological roles in 
angiogenesis, lymph-angiogenesis or metastasis (Table 2.2) and were selected for this 
project. 
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Table 2.1: Baseline characteristics for the 505 patients included in this study 
 
Variables N % 
Sex 
  Female 198 39.2 
Male 307 60.8 
Age at diagnosis median: 61.43 years (range: 20.7-75) 
 Histology 
  non-mucinous 448 88.7 
Mucinous 57 11.3 
Location 
  Colon 334 66.1 
Rectum 171 33.9 
Stage 
  I 93 18.4 
II 196 38.8 
III 166 32.9 
IV 50 9.9 
Grade 
  well/moderately differentiated 464 91.9 
poorly differentiated 37 7.3 
Unknown 4 0.8 
Vascular invasion 
  Absent 308 61 
Present 159 31.5 
Unknown 38 7.5 
Lymphatic invasion 
  Absent 298 59 
Present 167 33.1 
Unknown 40 7.9 
OS status 
  Alive 334 66.1 
Dead 170 33.7 
Unknown 1 0.2 
OS follow up time median: 6.36 years (range: 0.38-10.88) 
 DFS status 
  recurrence, metastasis or death (-) 304 60.2 
recurrence, metastasis or death (+) 200 39.6 
Unknown 1 0.2 
DFS follow up time median: 6 years (range: 0.22-10.88) 
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Familial risk 
  low risk 250 49.5 
moderate/high risk 255 50.5 
MSI status 
  MSI-L/MSS 431 85.3 
MSI-H 53 10.5 
Unknown 21 4.2 
Tumour BRAF Val600Glu 
mutation 
  Absent 411 81.4 
Present 47 9.3 
Unknown 47 9.3 
adjuvant chemotherapy status 
  not given 224 44.4 
Given 277 54.9 
Unknown 4 0.79 
adjuvant 5-FU based chemotherapy  
status 
 not given 230 45.5 
Given 261 51.7 
Unknown 14 2.8 
adjuvant radiotherapy status 
  not given 364 72.1 
Given 124 24.6 
Unknown 17 3.4 
 
OS: Overall Survival, DFS: Disease Free Survival, 5-FU: 5-Fluorouracil, MSI-H: microsatellite 
instability-high; MSI-L: microsatellite instability-low, and MSS: microsatellite stable  
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Table 2.2: Angiogenesis, lymph-angiogenesis and matrix metalloproteinase genes 
selected for this project and their genome coordinates  
 
Gene symbol Chromosome Start (bp) End (bp) 
VEGFA 6 43737946 43754223 
VEGFB 11 64002056 64006736 
VEGFC 4 177604691 177713895 
VEGFD X 15363713 15402535 
PGF 14 75408533 75422467 
VEGFR1 13 28874483 29069265 
VEGFR2 4 55944426 55991762 
VEGFR3 5 180028506 180076624 
MMP1 11 102660641 102668966 
MMP2 16 55513081 55540586 
MMP3 11 102706528 102714342 
MMP7 11 102391239 102401478 
MMP8 11 102582526 102595685 
MMP9 20 44637547 44645200 
MMP10 11 102641233 102651359 
MMP11 22 24115036 24126503 
MMP12 11 102733464 102745764 
MMP13 11 102813721 102826463 
MMP14 14 23305793 23316803 
MMP15 16 58059282 58080804 
MMP16 8 89049460 89339717 
MMP17 12 132312941 132336316 
MMP19 12 56229214 56236767 
MMP20 11 102447566 102496063 
MMP21 10 127455027 127464390 
MMP23B 1 1567560 1570030 
MMP24 20 33814539 33864804 
MMP25 16 3096682 3110724 
MMP26 11 5009424 5013659 
MMP27 11 102562415 102576468 
MMP28 17 34092876 34122640 
The 23 MMPs listed above are the only MMPs in the human genome based on the information in 
the HUGO database (205).  
MMPs 
 VEGF Ligands 
 
  VEGF Receptors 
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2.7. Patient SNP genotype data 
After the patients and genes to be included in this study were determined, the next 
step was to identify the SNPs to be investigated. We investigated SNPs irrespective of 
exonic or intronic locations along the genes. The genotyping platform annotates the 
genomic positions based on the human genome assembly hg19 (GRCh37). Hence, 
genome coordinates for each gene selected were retrieved using the UCSC genome 
browser (hg.19) (Table 2.2; 272, 273). If a gene had multiple transcripts, the genome 
coordinates of the longest isoform were retrieved so that all SNPs located in the gene 
region could be investigated. Using the genome coordinate information is a practical 
solution as by a single PLINK application (274, 275), patient genotype information for 
each SNP located within the genome coordinates (thus within the genes) could be 
retrieved from the bfiles. 
Next, a new bfile was created using PLINK (274, 275). This bfile contained the 
genotype data of the 505 patients included in the analysis. In addition, as a quality control 
measure, SNPs whose genotype frequencies deviated from the Hardy-Weinberg 
Equilibrium (HWE; p ≤0.0001) were excluded from this bfile. Also, this bfile only 
contained the SNPs with ≤5% missing genotype data as well as the SNPs with minor 
allele frequencies (MAFs) ≥5%. Once this new bfile was created, using the genome 
coordinates of genes as an input file, the genotype and other information related to SNPs 
were retrieved using PLINK (274, 275). 
The number of SNPs for the 31 genes is shown in Table 2.3. For one of the MMP 
genes (MMP23B) there was no SNP genotype data in the patient cohort. Thus our final 
analysis included 381 SNPs in 30 genes (Appendix A).  
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Table 2.3: Number of SNPs in genes studied in this project 
 
Gene Number of SNPs 
VEGFA 11 
VEGFB 2 
VEGFC 19 
VEGFD 7 
PGF 2 
VEGFR1 49 
VEGFR2 19 
VEGFR3 20 
MMP1 10 
MMP2 22 
MMP3 4 
MMP7 5 
MMP8 9 
MMP9 6 
MMP10 11 
MMP11 3 
MMP12 3 
MMP13 4 
MMP14 9 
MMP15 4 
MMP16 70 
MMP17 13 
MMP19 3 
MMP20 21 
MMP21 3 
MMP23B - 
MMP24 25 
MMP25 7 
MMP26 1 
MMP27 17 
MMP28 2 
Total = 31 Total = 381 
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Almost all of the variants were SNPs (n=380) while one was an insertion/deletion 
(indel). For simplicity, I refer to all of these variants as SNPs in this thesis. Each of the 
381 SNPs was manually confirmed to be located in these genes using the dbSNP (276) 
and UCSC databases (272, 273). The PLINK extracted data were then processed in 
Microsoft® Excel for further analysis. 
 
2.8. Variable coding and estimation of the best genetic model for each SNP  
The variables for the clinicopathological, molecular, and treatment-related 
features (Table 2.1) were categorized as follows: sex (females=0, males=1), tumor 
histology (non-mucinous=0, mucinous=1), tumor location (colon=0, rectum=1), tumor 
stage (stage I=1, II=2, III=3, and IV=4), tumor grade (well or moderately 
differentiated=0, poorly differentiated=1), vascular invasion (absent=0, present=1), 
lymphatic invasion (absent=0, present=1), familial risk (low=0, high/intermediate=1), 
MSI status (MSS/MSI-L=0, MSI-H=1), BRAF-Val600Glu mutation status (wild-type=0, 
mutated=1), adjuvant chemotherapy given (no=0, yes=1), adjuvant 5-FU-based 
chemotherapy given (no=0, yes=1), and adjuvant radiotherapy (no=0, yes=1). Age was 
analyzed as a continuous variable. 
The major allele (the more frequent allele) and the minor allele (the less frequent 
allele) for each SNP were determined based on the patient cohort genotype data. The 
genotype data obtained was coded in several different ways depending on the purpose. 
Traditionally, in the absence of information on the true underlying genetic model, the 
effects of polymorphisms on outcome is investigated by using one or more of the four 
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genetic models: additive, co-dominant, dominant and recessive. These genetic models are 
described elsewhere (277). Briefly, assuming the models are modeled based on the minor 
alleles (the least frequent allele in the patient cohort); in the dominant genetic model the 
survival times of patients with the homozygous minor allele (aa) and heterozygous 
genotypes (Aa) are compared with the survival times of patients with the homozygous 
major allele genotype (AA). In the recessive genetic model, the survival times of patients 
with the homozygous minor allele genotype (aa) are compared with the survival times of 
patients with the homozygous major allele (AA) or heterozygous (Aa) genotypes. In the 
co-dominant model, the survival times of patients with the heterozygous (Aa) and 
homozygous minor allele genotypes (aa) are compared separately to survival times of 
patients with the homozygous major allele genotype (AA). In the additive genetic model, 
the survival times of patients with the homozygous minor allele (aa), heterozygous (Aa) 
and homozygous major allele (AA) genotypes are analyzed simultaneously as a 
continuous variable. 
For this project, I applied a previously published strategy to estimate the best 
genetic model for each SNP using the Kaplan Meier survival curves constructed assuming 
the co-dominant genetic model (277). The main advantage of this strategy is that it helps 
estimates the best genetic model for each SNP based on their characteristics, rather than 
applying one or more genetic models randomly to the whole set of polymorphisms (277). 
There are other ways to determine the best genetic models for SNPs. For example, the 
SNP data can be investigated for each of the genetic models by separate univariable Cox 
regression analysis and the genetic model with the lowest p-value can be deemed to be 
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the best fitting genetic model (278). However, this approach creates a multiple testing 
issue because of large number of tests performed (277).  
In this study, first, the patient genotypes were coded assuming the co-dominant 
genetic model (or additive; both coding are identical) by using a PLINK command. 
Kaplan Meier survival analysis (279) was performed for each of the 381 SNPs to choose 
the genetic model that best fit each SNP. This analysis was done separately for OS and 
DFS. The Kaplan Meier survival curves were then inspected by two individuals (the 
author and supervisor). By looking at the pattern of the curves, one can estimate which 
genetic model or models (dominant, recessive, co-dominant or additive) may best fit the 
genotypes of a polymorphism. When in doubt, multiple genetic models were chosen. In 
cases where Kaplan Meier curves did not separate well or clear enough for us to estimate 
a genetic model, polymorphism were excluded from further statistical analysis. I 
examined the SNPs with the number of aa genotype <10 using the dominant genetic 
model. Results of this analysis are summarized in Table 2.4.  
After this step, genotypes were re-coded using a Microsoft® Excel function for 
the genetic model assigned to each SNP. The genotype data were then combined with the 
clinicopathological, demographic, molecular and prognostic data of the patients in 
Microsoft Excel® sheets. The files were then imported into IBM SPSS software (v.19 
and v.20) for statistical analysis. 
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Table 2.4: Summary of the best genetic models predicted for the 381 SNPs 
 Estimated genetic model Number of SNPs 
 
OS DFS 
Recessive only 137 136 
Dominant only 104 103 
Co-dominant only 29 41 
Additive only 0 0 
Multiple genetic models 20 29 
*Excluded 91 72 
Total 381 381 
 
*SNPs excluded from further analysis when their Kaplan Meier curves did not separate clear 
enough to estimate a genetic model. 
 
 
2.9. Gene-based haplotype survival analysis 
In order to perform the haplotype-survival association analysis, the phased 
haplotypes for each gene in each patient were estimated using PHASE II (v.2.1.1) 
software (261, 262). PHASE II also estimated the haplotype frequencies.  
In brief, PHASE II software was downloaded from the site of University of 
Chicago (www. http://stephenslab.uchicago.edu/software.html#phase) (280). Input text 
files that contained the SNP genotype data of the patient cohort were created for each 
gene separately using Perl programs written by Salem Werdyani. Input files were created 
for 29 genes, as the MMP26 gene had a single SNP genotyped and thus haplotype 
estimation was not relevant. Then using the PHASE II commands, the phased haplotypes 
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for each patient were estimated. To increase the accuracy of predictions, the estimations 
were performed for five rounds as recommended by the PHASE II developer. 
For the X-chromosome-linked genes (e.g. FIGF in this project), the PHASE II 
input files were created differently as recommended by the software developer. For FIGF, 
the males were paired separately in a file and assigned as “known individuals” (as males 
have one X chromosome, their X-linked haplotypes are easily deducible). In contrast, the 
female individuals were paired and assigned as “unknown individuals”. Preparation of 
input files and estimation of haplotypes for this gene were then preceded as explained 
above.  
After the phased haplotypes were estimated for each gene, the haplotypes together 
with haplotype frequency information generated by PHASE II were combined in 
Microsoft® Excel files. In the survival analysis, survival of the patients with either one or 
two copies of the most frequent haplotype for each gene was compared with the survival 
of patients with the remaining haplotypes. I limited this study to the genes that had at 
least one haplotype in ≥ 5% of the patients. As a result, two genes, VEGFR1 and MMP16, 
which did not have a frequent haplotype, were excluded. For FIGF, which is an X-linked 
gene, patients with either one copy (all males and females with one copy of the most 
frequent haplotype) or two copies (females only) were categorized together and compared 
with the patients with other haplotypes. For the haplotype-based analysis of the remaining 
genes, since the effect of the most common haplotype in homozygous and heterozygous 
state when compared to the remaining haplotypes (named as “other haplotypes 
throughout the thesis document) can be different from each other, similar to the SNP 
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analysis, I first estimated the best genetic model describing the effect of haplotype 
variables using the Kaplan Meier curves (Section 2.8).  
Table 2.5 shows the number of different haplotypes estimated for each gene in 
this analysis. Table 2.6 and Table 2.7 summarize the best genetic model estimated for the 
haplotype variables in each gene for OS and DFS, respectively.  
 
2.10. Measures of outcome 
Overall survival (OS) was analyzed using the OS status and OS time (the time 
from diagnosis until the time of death from any cause). Disease-free survival (DFS) was 
analyzed using the DFS status and DFS time (time from diagnosis to the time of 
recurrence, metastasis or death from any cause). When a patient did not experience these 
events, they were censored at the date of the last follow-up. 
 
2.11. Univariable survival analyses 
The purpose of univariable analyses is to test for association between a variable 
(such as a genotype or a baseline variable) and the outcome of interest (in this case, 
overall or disease-free survivals). In this study, Kaplan-Meier survival and Cox regression 
methods were used for univariable survival analyses. The Kaplan-Meier curves show 
patients’ survival characteristics and were used to select the best genetic model for each 
SNP and haplotype variables. On the other hand, the univariable Cox-regression analysis 
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Table 2.5: Number of phased haplotypes predicted for each gene 
 
Gene Number of common haplotypes (frequencies ≥ 5%) 
VEGFA 7 
VEGFB 3 
VEGFC 5 
VEGFD 4 
PGF 2 
*VEGFR1 none 
VEGFR2 2 
VEGFR3 5 
MMP1 7 
MMP2 6 
MMP3 5 
MMP7 4 
MMP8 5 
MMP9 4 
MMP10 7 
MMP11 3 
MMP12 4 
MMP13 3 
MMP14 8 
MMP15 3 
*MMP16 none 
MMP17 3 
MMP19 3 
MMP20 8 
MMP21 3 
MMP24 5 
MMP25 5 
MMP27 6 
MMP28 3 
 
*There were no haplotypes estimated with frequencies ≥ 5% in these two genes (VEGFR1 and 
MMP16). These genes therefore were not investigated during the haplotype association analysis. 
MMP26, for which only one SNP was investigated, is not included in this table. 
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Table 2.6: The best genetic models predicted for haplotype-based variables (overall 
survival) 
 
Genes  Best predicted model for each gene (haplotypes)  
VEGFA Recessive 
VEGFB *Excluded 
VEGFC Dominant 
VEGFD *Excluded 
PGF Co-dominant 
FLT4 Dominant 
KDR Dominant 
MMP1 Recessive 
MMP2 Recessive 
MMP3 Recessive 
MMP7 Dominant 
MMP8 Recessive 
MMP9 *Excluded 
MMP10 Recessive 
MMP11 Dominant 
MMP12 Recessive 
MMP13 *Excluded 
MMP14 Dominant 
MMP15 Co-dominant, dominant 
MMP17 Recessive, co-dominant 
MMP19 Additive, recessive, co-dominant, dominant 
MMP20 Dominant 
MMP21 Recessive 
MMP24 Recessive 
MMP25 Co-dominant 
MMP27 Recessive 
MMP28 Dominant 
*Excluded from statistical analyses as the Kaplan Meier curves of the haplotype variables did not 
separate clear enough to predict a genetic model. 
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Table 2.7: The best genetic models predicted for haplotype-based variables (disease-
free survival) 
 
Genes  Best predicted model for each gene (haplotypes)  
VEGFA Recessive 
VEGFB Dominant 
VEGFC Co-dominant, recessive 
VEGFD *Excluded 
PGF Recessive 
FLT4 Dominant 
KDR Dominant 
MMP1 Co-dominant 
MMP2 Recessive 
MMP3 Recessive 
MMP7 Dominant 
MMP8 Recessive 
MMP9 *Excluded 
MMP10 Recessive, dominant 
MMP11 Dominant 
MMP12 Recessive 
MMP13 Co-dominant 
MMP14 Dominant 
MMP15 Recessive 
MMP17 Recessive 
MMP19 Additive, recessive, co-dominant, dominant 
MMP20 Dominant 
MMP21 Recessive 
MMP24 Recessive 
MMP25 Co-dominant 
MMP27 Recessive 
MMP28 Dominant 
*Excluded from statistical analyses as the Kaplan Meier curves of the haplotype variables did not 
separate clear enough to predict a genetic model.  
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estimates a p value and the hazard ratio (HR) with 95% confidence intervals (CIs) (281). 
Univariable Cox regression analysis was performed for those SNPs and haplotypes for 
which a genetic model was chosen based on the Kaplan Meier curves. 
Univariable analysis was also performed for the clinicopathological, molecular 
and treatment-related variables in order to identify the baseline variables that would be 
entered into the multivariable model, together with the SNP genotypes or haplotypes that 
met the significance threshold requirements. Appendix B and Appendix C show the 
univariable Cox regression analysis results for these variables for overall survival and 
disease free survival, respectively. The significance threshold set for the baseline 
variables as well as the haplotype-based analysis was p<0.05. Due to the large number of 
polymorphisms investigated, to account for multiple testing while also limiting the false-
negative associations (i.e. when there is a real association, which is missed because of a 
conservative multiple testing correction), the significance threshold for association of the 
polymorphisms was set at p<0.001 prior to statistical analysis. Univariable analyses were 
conducted using IBM SPSS (version 19 and 20). The results were then exported from 
IBM SPSS into Microsoft® Excel sheets. 
 
2.12. Identification of highly correlated variables  
Spearman’s correlation test was used to check whether the variables investigated 
were highly correlated. Variables with a correlation score (rs) ≥0.8 were deemed to be 
highly correlated. This information is very important because multicollinearity in a model 
may inflate the standard errors, thus making some variables appear statistically 
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insignificant while they should be significant or vice versa (282). To avoid this situation, 
one of the correlated variables should be excluded from the final multivariable model.  
This test was performed for the baseline, molecular and treatment-related 
characteristics as well as for the SNPs that were significantly associated with outcomes in 
the univariable analysis. Based on the results of this test, only lymphatic and vascular 
invasion (rs
 
= 0.963), and adjuvant chemotherapy and adjuvant 5-FU-chemotherapy status 
(rs
 
= 0.992) were highly correlated with each other. Among these variables, I reasoned 
that the one with the smallest p-value in the univariable analysis and with less missing 
data should be included in the baseline multivariable (MVA) model. On this basis, 
vascular invasion and adjuvant 5-FU-based chemotherapy were included in the baseline 
models. Of note, none of the SNPs that were significantly associated with outcome in the 
univariable analysis was associated with these baseline variables. 
 
2.13. Multivariable Cox regression analysis 
Multivariable Cox regression analysis assesses whether several covariates 
independently influence outcome, i.e. it shows the independent predictive potential of 
each variable in a model (282). I performed this analysis for three purposes: a) to identify 
the baseline variables that would be included in the final multivariable models, b) to 
construct the final multivariable models containing both the baseline variables and the 
SNPs, and c) to construct the multivariable models containing both the baseline variables 
and the haplotypes.  
In order to get our baseline model, the clinicopathological, molecular, and 
treatment-related baseline variables with p <0.05 in the univariable Cox regression 
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analysis were entered into multivariable models for OS and DFS separately. As explained 
in Section 2.12, in the case of variables that were highly correlated with each other, one 
of them was excluded from this analysis. The baseline variables that remained significant 
after this analysis were selected to enter the final multivariable model together with the 
polymorphisms or haplotype variables significantly associated with outcomes in the 
univariable analyses. As a result, stage and MSI status remained significant for both 
overall and disease-free survival in the multivariable models. Age was not significant in 
our analysis, but since it is a well-established prognostic marker, especially in overall 
survival, I opted to construct our final multivariable models both with and without age as 
a covariate. These analyses were conducted using the IBM SPSS (version 19 and 20). The 
results were then exported from IBM SPSS and organized in Microsoft Excel® spread 
sheets. 
 
2.14. Construction of linkage disequilibrium map of the genomic region 
encompassing the MMP8 and MMP27 genes 
A linkage disequilibrium (LD) map of the genomic region containing the MMP8 
and MMP27 genes was constructed using Haploview 4.2 software (283). In order to 
construct the LD map, the genotypes for the polymorphisms located within the genomic 
region of these two genes were first extracted using PLINK. These data were then 
formatted and used in the Haploview to visualize the LD map of the region.   
56 
 
Chapter 3: Results 
 
3.1. Univariable survival analyses 
 
3.1.1 Single SNP survival association analysis 
In this study, 381 polymorphisms genotyped in a cohort of 505 colorectal cancer 
patients were investigated for their associations with survival outcomes. Kaplan Meier 
curves were constructed in order to choose the genetic model that best fits each SNP 
(277). Figure 3.1 shows examples of the Kaplan Meier curves constructed for this 
purpose. As a result of this analysis, I was able to choose the best genetic model(s) for 
290 and 309 SNPs for overall survival and disease-free survival, respectively (Table 2.4). 
These SNPs were then investigated in a Cox univariable analysis. 
 
Polymorphisms associated with overall survival 
Of the polymorphisms investigated, three SNPs were found to be significantly 
associated with overall survival and all of these associations were observed under the 
dominant genetic model. The results of univariable Cox regression analysis for these 
SNPs and overall survival are summarized in Table 3.1. The minor allele was protective 
in all three SNPs (minor allele frequency ~ 27%). For the MMP8-rs12365082 
(NM_002424.2:c.*1247A>T) polymorphism, I observed that patients with the TA or AA 
genotypes were at lower risk of death compared to patients with the TT genotype (Table 
3.1; Figure 3.2.a). 
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Figure 3.1: Examples of Kaplan-Meier survival plots  
 
                      
 
 
 
MMP3-rs3020919 C/T MMP8-rs12365082 T/A 
Minor allele: A Minor allele: T 
Best-fit model: 
 
Co-dominant  
Best-fit model: 
Dominant  
  CT 
 CC 
TT 
TT 
TA 
AA 
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MMP1-rs10488 G/A MMP8-rs2012390 T/C 
Minor allele: C Minor allele: A 
TT 
Best-fit model: 
 *Dominant  
Best-fit model: 
 
Recessive  
TC 
CC 
GA 
GG 
 AA 
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Blue = major allele homozygotes, green = heterozygotes, beige = minor allele homozygotes. *An example of a case where the dominant 
genetic model was chosen by default as the number of patients with the minor allele homozygote genotype (aa) was less than 10.  
 
MMP16-rs3851539 A/G 
Minor allele: G 
None 
Best genetic model chosen 
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Table 3.1: Polymorphisms associated with overall survival in the univariable 
analysis (dominant genetic model) (n= 504) 
SNP 
Genotype 
categories p-value HR 
95% CI for HR Minor 
allele 
(MAF) Lower Upper 
MMP8-rs12365082 TA +AA vs TT 0.0006 0.579 0.423 0.791 A (0.2683) 
MMP27-rs11225388 AG + GG vs AA 0.0005 0.574 0.42 0.785 G (0.2693) 
MMP27-rs11225389 CA + AA vs CC 0.0005 0.574 0.42 0.785 A (0.2693) 
HR: hazard ratio, CI: confidence interval 
 
 
For the MMP27-rs11225388 (NM_022122.2:c.103-233T>C) polymorphism, 
patients with AG or GG genotypes had a longer overall survival than those with the AA 
genotype (Table 3.1; Figure 3.2.b). Finally, patients carrying the CA or AA genotypes of 
the MMP27-rs1225389 (NC_000007.14:g.155851799T>A) polymorphism had longer 
overall survival than those homozygous for the major allele (CC genotype) (Table 3.1; 
Figure 3.2.c). None of the remaining SNPs tested were associated with overall survival at 
the significance threshold of p = 0.001.  
Upon further investigation, I found that the genotypes of these three SNPs were 
highly correlated with each other (Spearman’s correlation coefficient rs values: between 
MMP8-rs12365082 and MMP27-rs11225388 = 0.997, MMP8-rs12365082 and MMP27-
rs1225389 = 0.996, and between MMP27-rs11225388 and MMP27-rs1225389 = 0.999). 
The MMP8 and MMP27 genes are close to each other on chromosome 11 where there is a 
cluster of nine MMP genes (Figure 3.3). 
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Figure 3.2: Kaplan-Meier survival plots for the three polymorphisms associated with overall survival 
 
    
a. MMP8-rs12365082 T/A b. MMP27-rs11225388 A/G 
Minor allele: G Minor allele: A 
  TT 
TA + AA  AG + GG 
AA 
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Blue = major allele homozygous genotype, green = heterozygous and homozygous minor allele genotypes        
                  
Minor allele: A 
c. MMP27-rs11225389 C/A 
CA +AA 
CC 
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Figure 3.3: The MMP gene cluster on chromosome 11q22. 
…….
6,058 bp
rs11225388rs11225389 
rs12365082
MMP27 (14,049 bp) MMP8 (13,159 bp)
7,093 bp
MMP7 MMP20 MMP27 MMP8 MMP10 MMP1 MMP3 MMP12 MMP13
~43, 5224bp
MMP genes cluster on Chromosome 11q22
The MMP27 and MMP8 genes are 14,049 and 13,159 base pairs long, respectively. The distance 
between the MMP27-rs11225388 and MMP8-rs12365082 polymorphisms is 7,093 base pairs. 
Figure not drawn to scale. Chromosomal bar is obtained from the UCSC genome browser website 
(272, 273). 
 
 
Polymorphisms associated with disease-free survival 
In the univariable analysis, none of the polymorphisms investigated in this study 
were found to be associated with disease-free survival in our patient cohort at the 
significance threshold of p= 0.001. 
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3.1.2 Haplotype-based survival analysis 
We performed haplotype survival association analyses in relation to both overall 
and disease-free survivals. Univariable survival analysis was performed for the 
haplotypes estimated for 27 genes. One gene without multiple polymorphisms (MMP26) 
and two genes without common haplotypes with frequencies ≥5% (VEGFR1 and 
MMP16) were excluded from the haplotype analysis. The purpose of the analysis was to 
compare survival times of patients with one or two copies of the most frequent haplotype 
with the survival times of patients with the remaining haplotypes (Section 2.9). Similar to 
the approach used for SNP associations, Kaplan Meier curves were constructed to select 
the genetic model that best fit each haplotype category (Section 2.8). Haplotypes not 
distinguished by the Kaplan Meier curves (n = 4 for overall survival and n = 2 for 
disease-free survival) were excluded from further analysis (Table 2.6 and Table 2.7). The 
remaining haplotypes (n = 23 for overall survival and n = 25 for disease free survival) 
were further investigated by Cox univariable analysis.  
 
Haplotypes associated with overall survival  
Haplotypes of three genes were associated with overall survival under the 
recessive (Table 3.2; MMP3, MMP27) or co-dominant (Table 3.2; MMP25) genetic 
models. For MMP3, patients homozygous for the most common haplotype had longer 
survival than patients with one or no copies of the most common haplotype (Table 3.2; 
Figure 3.4.a). An increased hazard was observed in patients homozygous for the most 
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common MMP27 haplotype compared to those with a single copy of the most common 
haplotype or patients with other haplotypes (Table 3.2; Figure 3.4.b).  
 
Table 3.2: Haplotypes associated with overall survival in a univariable survival 
analysis (n= 504) 
 
Variable p-value HR 
95% CI for HR 
Genetic model Lower Upper 
*MMP3 haplotype 0.007 0.533 0.337 0.842 Recessive 
*MMP27 haplotype 0.03 1.523 1.041 2.228 Recessive 
MMP25 haplotype 0.032            Co-dominant  
**MMP25 haplotype 0.009 1.518 1.109 2.078 
 ***MMP25 haplotype 0.651 1.146 0.635 2.065   
 
HR: hazard ratio, CI: confidence interval 
*patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes 
**patients heterozygous for the most common haplotype vs patients with other haplotypes 
***patients homozygous for the most common haplotype vs patients with other haplotypes 
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Figure 3.4: Kaplan-Meier survival plots for the haplotypes associated with overall survival 
 
       
a. MMP3-haplotype b. MMP27-haplotype 
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a) The best-fit model: recessive. Blue = other haplotypes or one copy of the most common haplotype. Green = two 
copies of the most common haplotype. 
b) The best-fit model: recessive. Blue = other haplotypes or one copy of the most common haplotype. Green = two 
copies of the most common haplotype. 
c) The best-fit model: co-dominant. Blue = other haplotypes. Green = one copy of the most common haplotype 
(heterozygotes). Beige = two copies of the most common haplotype (homozygotes).  
c. MMP25-haplotype 
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Finally, I found that patients heterozygous for the most frequent MMP25 
haplotype had a higher risk of death compared to patients with other haplotypes (Table 
3.2; Figure 3.4.c). Of note, there was no association between homozygosity for the most 
common MMP25 haplotype and overall survival (Table 3.2).  
The most common haplotypes of the MMP3, MMP25, and MMP27 genes were 
quite frequent in the patient cohort (Table 3.3). The polymorphisms and alleles that 
constituted the most common haplotypes in these genes are shown in Table 3.4. The 
haplotypes consisted of four SNPs in MMP3, seven SNPs in MMP25 and 17 SNPs in 
MMP27. 
 
Table 3.3: Frequencies of the most common haplotypes for the five genes associated 
with survival in univariable analyses 
Genes Frequency 
Survival times 
Associated 
MMP3 44.16 OS, DFS 
MMP25 28.71 OS, DFS 
MMP27 39.96 OS, DFS 
MMP8 44.88 DFS 
MMP21 45.77 DFS 
 
OS: overall survival, DFS: disease-free survival 
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Table 3.4: The most common haplotypes (frequency ≥ 5%) for the three genes 
associated with overall survival in univariable analyses 
 
Gene Haplotype Frequency 
MMP3 CACA 0.441604 
MMP27  CCGTAAAACCAAAGAGC 0.399644 
MMP25 TCGCTGC 0.287138 
 
The rs numbers for the SNPs in each haplotype (starting with the SNP with the smallest genome 
coordinate along the chromosome where the gene is located to the SNP with the largest) is; 
 
MMP3: rs566125, rs3025066, rs3020919 and rs679620  
 
MMP27: rs2509010, rs11607205, rs1276289, rs11821641, rs1276286, rs2846723, rs2846701, 
rs2846703, rs3809018, rs4754870, rs17099425, rs11225386, rs11225388, rs2846707, rs1939015, 
rs12099177 and rs11225389 
 
MMP25: rs2247226, rs10431961, rs7199221, rs1064875, rs1064948, rs11864930 and 
rs10438593 
 
 
Haplotypes associated with disease-free survival 
The results obtained in the univariable analysis are summarized in Table 3.5. Five 
genes were associated with disease-free survival: four under a recessive model (MMP3, 
MMP8, MMP21, and MMP27) and one under a co-dominant model (MMP25) (Figure 
3.5). 
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Table 3.5: Haplotypes associated with disease-free survival in univariable survival 
analyses (n= 503) 
 
Variable p-value HR 
95% CI for HR 
Genetic model 
Lower Upper 
*MMP3 haplotype 0.021 0.625 0.419 0.932 Recessive 
*MMP8 haplotype 0.01 1.521 1.103 2.095 Recessive 
*MMP21 haplotype 0.032 0.657 0.448 0.964 Recessive 
*MMP27 haplotype 0.027 1.484 1.046 2.107 Recessive 
MMP25 haplotype 0.121        Co-dominant  
**MMP25 haplotype 0.048 1.338 1.002 1.786 
 ***MMP25 haplotype 0.964 0.987 0.563 1.732  
 
HR: hazard ratio, CI: confidence interval 
*patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
** patients heterozygous for the most common haplotype vs patients with other haplotypes; 
*** patients homozygous for the most common haplotype vs patients with other haplotypes 
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Figure 3.5: Kaplan-Meier survival plots for the haplotypes associated with disease-free survival 
 
      
 
   
b. MMP8-haplotype a. MMP3-haplotype 
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d. MMP27-haplotype c. MMP21-haplotype 
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a) The best-fit model: recessive. Blue = patients with other haplotypes or one copy of the most common haplotype. 
Green = patients with two copies of the most common haplotype. 
b) The best-fit model: recessive. Blue = patients with other haplotypes or one copy of the most common haplotype. 
Green = patients with two copies of the most common haplotype. 
c) The best-fit model: recessive. Blue = patients with other haplotypes or one copy of the most common haplotype. 
Green = patients with two copies of the most common haplotype. 
d) The best-fit model: recessive. Blue = patients with other haplotypes or one copy of the most common haplotype. 
Green = patients with two copies of the most common haplotype. 
e) The best-fit model: co-dominant. Blue = patients with other haplotypes. Green = patients with one copy of the 
most common haplotype (heterozygotes). Beige = patients with two copies of the most common haplotype 
(homozygotes). 
 
e. MMP25-haplotype 
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Patients homozygous for the most common MMP3 haplotype had a 37% reduced 
risk of recurrence, metastasis or death when compared to other patients (Figure 3.5.a). 
Patients homozygous for the most common MMP8 haplotype had a greater risk of disease 
recurrence, metastasis or death when compared to other patients (Table 3.5; Figure 
3.5b). Patients homozygous for the most common MMP21 haplotype had a 34% reduced 
risk of event when compared to patients with a single copy of the most common 
haplotype or patients with other haplotypes (Table 3:5; Figure 3.5c). Patients 
homozygous for the most common MMP27 haplotype had a higher risk of recurrence, 
metastasis or death compared to other patients (Table 3.5; Figure 3.5d). Finally, in the 
case of the MMP25 gene, patients who were heterozygous for the most common 
haplotype had decreased disease-free survival times (Table 3.5; Figure 3.5e) when 
compared to patients with other haplotypes. Of note, the associations of MMP3, MMP27, 
and MMP25 haplotypes with disease-free survival were also observed in the overall 
survival analysis as described previously. The most common haplotype for each of these 
three genes is shown in Table 3.4. Table 3.6 shows the most common haplotypes for 
MMP8 and MMP21 (frequencies in the study cohort are shown in Table 3.3).  
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Table 3.6: The most common haplotypes (frequency ≥ 5%) for the genes associated 
with disease-free survival in univariable analyses 
 
Gene Haplotype Frequency 
MMP8 TGCGTCCAG 0.45 
MMP21 GTG 0.46 
 
The rs numbers for the SNPs in each haplotype (starting with the SNP with the smallest genome 
coordinate along the chromosome where the gene is located to the SNP with the largest) is; 
 
MMP8: rs12365082, rs7934972, rs12284255, rs3740938, rs2012390, rs1940475, rs6590984, 
rs3765620 and rs2155052 
 
MMP21: rs7922546, rs10901424 and rs12775804 
 
 
3.1.3 Survival analyses for baseline variables 
Univariable analyses were performed to determine associations between baseline 
clinicopathological, molecular and treatment-related characteristics and survival times. 
The results were used to identify the variables to be included in the final multivariable 
models, together with the SNPs and haplotypes that were associated with overall or 
disease-free survivals in the univariable analyses. 
 
Baseline variables associated with overall survival 
Appendix B shows the results of a univariable Cox regression analysis for the 
baseline variables and overall survival. Of 14 baseline variables tested in the univariable 
analysis, five were associated with overall survival (sex, stage, vascular invasion, 
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lymphatic invasion and MSI). Appendix D shows the Kaplan Meier curves for these 
variables. As expected, male patients had a significantly higher risk of death than did 
females. Patients with stage III and stage IV disease had increased risks of death 
compared to those with stage I disease. Patients with vascular or lymphatic invasions of 
the tumour showed significantly greater hazard of death than did patients with no vascular 
or lymphatic invasions. Finally, patients with MSI-H tumor status had a lower risk of 
death than did patients with MSS or MSI-low tumors. 
 
Baseline variables associated with disease-free survival 
The results of a univariable Cox regression analysis for the baseline 
clinicopathological, molecular, and treatment-related variables and disease-free survival 
are summarized in Appendix C. Six variables were associated with disease-free survival 
as expected (sex, stage, location, vascular invasion, lymphatic invasion, and MSI status). 
Male patients had greater risks of disease recurrence, metastasis or death compared to the 
female patients. Patients with rectal cancer had shorter disease-free survival times 
compared to those with colon cancer. Shorter disease-free survival times were also 
observed in stage III and stage IV patients compared to stage I patients. Patients with 
vascular or lymphatic tumor invasion showed higher risk of disease recurrence, metastasis 
or death than patients with tumors lacking vascular or lymphatic invasion. Finally, 
patients having MSI-H tumors had reduced risk of events (disease recurrence, metastasis 
or death) when compared to patients with MSS or MSI-low tumors. Kaplan Meier curves 
for the variables significantly associated with disease free survival are shown in 
Appendix E. 
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3.2. Multivariable survival analysis  
Selection of baseline covariates for the final multivariable models is described in 
Section 2.13. Appendix F and Appendix G show the results of a baseline multivariable 
Cox regression analysis results for overall survival and disease-free survival, respectively. 
The SNPs and haplotypes that met the significance threshold in the univariable analysis 
were entered into separate multivariable models together with the selected baseline 
variables, namely stage and MSI status. As explained in Section 2.13, age was not 
significantly associated with either overall or disease-free survivals in univariable 
analyses. Yet considering the fact that age is a well-established prognostic marker, 
especially in overall survival, multivariable models which include age as a covariate are 
also reported. 
 
Multivariable analysis for polymorphisms associated with overall survival in the 
univariable analysis 
 As described in Section 3.1.1, the genotypes of the three polymorphisms (MMP8-
rs12365082, MMP27-rs11225388, and MMP27-rs11225389) found to be associated with 
overall survival in the univariable analysis are highly correlated with each other (rs 
>0.996). I therefore chose one of these polymorphisms (MMP27-rs11225388) to perform 
the multivariable analysis.  
After adjusting for stage and MSI status, patients with an AG or GG genotype of 
the MMP27-rs11225388 polymorphism had lower risk of death than did patients with an 
AA genotype (Table 3.7a). When adjusted for age at diagnosis, stage, and MSI status 
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(Table 3.7b), a similar result was obtained. As expected, stage and MSI (as well as age) 
were independent predictors of overall survival. 
 
Results of the multivariable analysis for the haplotypes associated with overall and 
disease-free survival in the univariable analysis 
Of the three haplotypes associated with overall survival and five haplotypes 
associated with disease-free survival in a univariable analysis, the only association 
detected in the multivariable analysis was that of the MMP3 haplotype with overall 
survival. Table 3.8 shows the multivariable analysis results for overall survival, and 
Appendix H shows the result for disease-free survival performed for this haplotype. 
When adjusted only for stage and MSI status, patients with two copies of the most 
common MMP3 haplotype had better overall survival (Table 3.8a). Also, when adjusted 
for age at diagnosis, stage and MSI, a similar result was obtained (Table 3.8b). 
Appendices I-N show the results for the other haplotypes that were associated with 
survival in the univariable analyses, but not in the multivariable models. 
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Table 3.7: Results of the multivariable analysis for the MMP27 polymorphism and 
overall survival (dominant genetic model)  
 
a) Adjusting for stage and MSI status (n= 483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001 
    Stage II vs stage I 0.116 1.591 0.892 2.84 
 Stage III vs stage I 0.003 2.373 1.345 4.188 
 Stage IV vs stage 1 <0.001 9.398 5.152 17.142 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.189 0.07 0.512 
 MMP27-rs11225388 AG + GG vs AA 0.001  0.581 0.42 0.803   
 
      b) Adjusting for stage, age at diagnosis and MSI status (n= 483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001 
    Stage II vs stage I 0.118 1.588 0.89 2.834 
 Stage III vs stage I 0.002 2.509 1.419 4.439 
 Stage IV vs stage 1 <0.001 10.417 5.672 19.13 
 Age at diagnosis 0.02 1.021 1.003 1.04 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.191 0.07 0.517 
 MMP27-rs11225388 AG + GG vs AA 0.0013 0.589 0.426 0.814  
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable.  
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Table 3.8: Multivariable analysis for the MMP3 haplotype associated with overall 
survival (recessive genetic model)  
 
a) Adjusting for stage and MSI status (n= 483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.123 1.577 0.883 2.817 
 Stage III vs I 0.003 2.338 1.325 4.127 
 Stage IV vs I <0.001 9.717 5.335 17.699 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.188 0.069 0.509 
 *MMP3 haplotype 0.027 0.596 0.376 0.943   
 
b) Adjusting for age at diagnosis, stage and MSI status (n= 483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.016 1.022 1.004 1.040 
 Stage <0.001    
 Stage II vs I 0.132 1.561 0.874 2.788 
 Stage III vs I 0.002 2.457 1.390 4.343 
 Stage IV vs I <0.001 10.748 5.866 19.695 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.191 0.070 0.520 
 *MMP3 haplotype 0.029 0.600 0.379 0.950   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable. *patients homozygous for the most 
common haplotype vs patients heterozygous for the most common haplotype or patients with the 
other haplotypes. 
 
 
 
81 
 
3.3. Comparison of the entire NFCCR patient cohort (n=736) with patients included 
in this study (n=505) 
In order to determine whether the study cohort (n=505) was representative of the 
entire NFCCR cohort (n=736), we performed a Chi-square test for categorical variables. 
This analysis was done for clinicopathological, molecular and treatment-related features 
including sex, vascular invasion, grade, lymphatic invasion, location, histology, BRAF 
Val600Glu mutation status, MSI status, adjuvant 5-FU based chemotherapy, adjuvant 
chemotherapy and adjuvant radiation treatment status. The baseline characteristics of the 
NFCCR cohort are shown in Appendix O.  
I observed significant differences between the entire NFCCR cohort (n=736) and 
the patients included in this study (n=505) in terms of the distribution of stage (p-value 
<0.001). As also shown in Table 2.1 and Appendix P, the study cohort had significantly 
fewer stage IV patients (9.9%) (Appendix O) than the entire NFCCR cohort (20.8%). 
Significant differences were also detected for lymphatic and vascular invasion status: the 
entire NFCCR cohort had more patients with vascular invasion or lymphatic invasion 
when compared to the study cohort (38.3% versus 31.5%, p =0.011 and 38.7% versus 
33.1%, p =0.03, respectively) (Appendices Q and R). We also used the non-parametric 
Mann-Whitney U-test to compare the median age at diagnosis, and the overall survival 
and disease free survival times in the two cohorts: the study cohort had longer follow-up 
times when compared to the entire NFCCR cohort (p <0.001; Appendix S).  
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Chapter 4: Discussion 
 
The purpose of this study was to identify new prognostic markers in colorectal 
cancer. I investigated the associations between survival and 381 genetic polymorphisms 
(and their combinations in haplotypes) within select genes coding for vascular endothelial 
growth factors (VEGFs), their receptors (VEGFRs) and matrix metalloproteinases 
(MMPs). 
Substantial biological and clinical data show that variations in angiogenesis, 
lymph-angiogenesis and metastasis may influence patient survival (9, 10). These 
processes involve the protein products of several genes, such as members of the VEGF, 
VEGFR and MMP families. The vascular endothelial growth factor ligands or receptors 
(e.g. VEGFA, VEGFR1) and matrix metalloproteinases (e.g. MMP1, MMP3, and MMP9) 
play crucial roles in cancer progression (284, 285) or are associated with survival 
outcomes in patients (286-290). Due to the established roles of VEGF proteins in 
carcinogenesis and progression, drugs that target them have been developed for use in 
patient care (for example Bevacizumab targeting VEGFA (291) and Cabozantinib 
targeting VEGFR2 (292)). Based on this and other scientific knowledge, this study 
focused on VEGF ligands (n=5), VEGFRs (n=3) and all the known human MMP genes 
(n=23). 
The results of the study presented in this thesis suggest that three SNPs (MMP27-
rs11225389, MMP27-rs11225388, and MMP8-rs12365082) located within the MMP8 and 
MMP27 genes on chromosome 11q22 are associated with overall survival independent of 
age at diagnosis, disease stage, and MSI status. These SNPs are potential prognostic 
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indicators of survival in this disease. Specifically, patients with genotypes containing the 
minor allele had longer survival time than patients homozygous for the major allele. The 
genotypes of these three SNPs, which lie within an approximately 7 kb region, are highly 
correlated with each other (rs >0.99). The frequency of the minor allele in the study 
population is about 27%. Figure 4.1 shows the LD block structure of the genomic region. 
An intergenic SNP (rs12418360) is located between MMP8 and MMP27 (Figure 4.1). 
Since this SNP is intergenic, it was not initially included in this study. A survival analysis 
was performed for this SNP as well which found no association of this SNP with overall 
survival under the dominant genetic model (HR =1.362, 95% CI 0.907-2.044, p-value 
=0.136). Except for one SNP, the genotypes of other SNPs in the two LD regions (LD 
blocks 14 and 15, Figure 4.1) were not highly correlated with the genotypes of these 
three SNPs (Appendix T). While the three SNPs significantly associated with overall 
survival are almost always inherited together (correlation of their genotypes rs >0.99), it 
appears that SNPs not highly correlated with them are not consistently co-inherited. This 
can happen, for example, if the SNPs represent relatively new mutations. The only SNP 
correlated with the rs11225388, rs11225389, and rs12365082 SNPs was the MMP27-
rs2846707 (rs=0.8, Appendix T). However, our analysis did not find it significantly 
associated with overall survival in a univariable analysis at the pre-specified significance 
threshold (p-value = 0.0063, HR = 0.658, 95% CI = 0-487-0.889).  
 
84 
 
 
 
 
a. Chr. 11q22.2 
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b. A close view of LD blocks 14 and 15 showing the four SNPs. 
 
 
Figure 4.1a: LD block structure of the genomic region containing the nine MMP genes (MMP7, MMP20, MMP27, MMP8, MMP10, 
MMP1, MMP3, MMP12, and MMP13) on chromosome 11q22. Figure 4.1b: The blue circles show the three SNPs (rs11225389, 
rs11225388, and rs12365082) that were found to be associated with overall survival in this study (in LD blocks 14 and 15). The red circle 
indicates the intergenic SNP (rs12418360).  
    
86 
 
The MMP27-rs11225389, MMP27-rs11225388, and MMP8-rs12365082 
polymorphisms are all located in non-coding regions, specifically the 5’-UTR (MMP27-
rs11225389), 3’-UTR (MMP8-rs12365082) and intronic regions (MMP27-rs11225388). 
As of July 2014, there is no published report concerning their potential biological 
significance. According to a computational tool, snpinfor (293), these SNPs are predicted 
to be located within biologically functional regions. For example, the MMP27-
rs11225388 and MMP27-rs11225389 polymorphisms are located in binding sites of 
several transcription factors such as AP1, CDPCR3, TAXCREB and AP4, PAX6, 
PPARG, respectively (293). The MMP8-rs12365082 polymorphism is located in a 
binding site of a miRNA, hsa-miR (293). Thus, these polymorphisms may affect the 
expression levels of these genes. Further studies are needed to test the biological roles of 
these SNPs and their relation to progression in colorectal cancer. In addition, there is no 
previous report addressing the associations of these particular SNPs with clinical 
outcomes in colorectal cancer. To our knowledge, this is the first time these 
polymorphisms have been investigated and found to be associated with outcome in 
colorectal cancer.  
Four of the polymorphisms included in this study have previously been studied in 
relation to survival outcomes in colorectal cancer. Dassoulas et al. (227) found an 
association between the (VEGFA +936 C/T (rs3025039; NM_001025366.1:c.*237C>T) 
polymorphism) and overall survival. However, this association was not confirmed in the 
present study or in other studies (231, 233 and 265). In the case of the VEGFA-634 G/C 
(rs2010963; NM_001025366.1:c.-94C>G) polymorphism, the same group reported its 
association with overall survival (227). However, neither our study nor other studies 
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(231-233, 265) replicated this finding. These conflicting results between the present and 
other study may be due to the differences in patient ethnicities, treatment characteristics 
of the cohorts, the study design or the statistical approaches used, (such as the p-value 
threshold that defined the significance level). In addition, our present study found no 
association between another polymorphism (KDR 1192 C/T (rs2305948; 
NP_002244.1:p.Val297Ile)) with survival times as previously reported (232). Another 
graduate student in our laboratory had previously investigated the associations of 
VEGFA-634 G/C (rs2010963) and VEGFA +936 C/T (rs3025039; 
NM_001025366.2:c.*237C>T) SNPs, also included in this study, in a similar NFCCR 
patient sub-cohort (265). That study analyzed the genotypes using a co-dominant genetic 
model but, similar to our results, found no association of these SNPs with clinical 
outcome.  
To complement the single-SNP survival association approach, I also performed 
gene-based haplotype analysis, using phased haplotypes for each patient. The result of 
this analysis showed that one haplotype (in the MMP3 gene) was significantly associated 
with overall survival in patients when adjusted for other prognostic variables. This MMP3 
haplotype contains four SNPs: rs566125, rs3025066, rs3020919, and rs679620. To our 
knowledge, this is the first study to investigate and identify this haplotype as associated 
with outcome in colorectal cancer. The biological relevance of this haplotype to the risk 
of death in colorectal cancer patients is yet to be established. 
So far, very few studies have tested the associations of haplotypes with survival 
outcomes in colorectal cancer. Kim et al. (15) showed that a VEGFA haplotype consisting 
of the -2578C/A (rs699947; NM_001025366.2:c.-2055A>C), -634G/C (rs2010963; 
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NM_001025366.1:c.-94C>G), and +936C/T (rs3025039; NM_001025366.2:c.*237C>T) 
polymorphisms was associated with outcome in colorectal cancer patients. Hansen et al. 
(14) showed that a haplotype consisting of the VEGFA -2578C/A (rs699947; 
NM_001025366.2:c.-2055A>C), -460C/T (rs833061; NM_001025366.2:c.-958C>T) and 
405G/C (rs2010963; NM_001025366.2:c.-94C>G) polymorphisms was significantly 
associated with survival in a cohort of colorectal cancer patients. These studies may not 
be directly comparable to the present study which used different sets of SNPs and 
haplotypes. 
Interestingly, both the single SNP and the haplotype analysis in this study 
identified associations between the three matrix metalloproteinase genes (MMP8, 
MMP27, and MMP3) and overall survival in colorectal cancer. MMP8 also called 
neutrophil collagenase is mainly expressed in neutrophils. The MMP8 protein belongs to 
a group of extracellular proteases that have the ability to degrade the extracellular matrix 
(294). The role of MMP8 is the degradation of type I, II and III collagens. The second 
gene identified in this study, MMP27, encodes a matrix metalloproteinase that helps 
degrade extracellular matrix components such as fibronectin, gelatins and aggrecan (295). 
Somatic mutations of the MMP8 and MMP27 genes have been reported in some cancers 
(e.g. thyroid cancer, or melanoma) but not previously in colorectal cancer (296-298). 
MMP3 is another matrix metalloproteinase gene associated with survival outcomes in this 
study. The MMP3 protein degrades components of the extracellular matrix such as 
collagen IV, fibronectin, proteoglycan, and laminin (299). Many reports have associated 
mutations of this gene with diseases such as colorectal cancer (300), myocardial 
infarction (301), Takayasu arteritis (302), Alzheimer’s disease (303), and gastric cancer 
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(304). Interestingly, MMP3, MMP8, and MMP27 are all located in a MMP gene cluster 
on chromosome 11q22 (305) (Figure 4.1a). This is the first report that suggests an 
association between this chromosomal region and the risk of death in colorectal cancer. 
I am aware of the limitations of this study. Since we considered only common 
genetic variants and haplotypes (frequencies ≥ 5%) in the study population, I may have 
missed rare genetic variations or haplotypes that could have strong effects on prognosis. 
Similarly, in the haplotype analysis, I tested only the associations of the most common 
haplotype for each gene compared to other haplotypes. The potential prognostic 
associations of other individual haplotypes remain to be tested. Our study cohort is biased 
towards early stage patients. Stage IV patients and those with vascular or lymphatic 
invasion of the tumor are underrepresented when compared to the entire NFCCR cohort. 
This is because many late-stage patients were already deceased before being enrolled into 
the study and therefore no blood sample could be obtained for DNA extraction (deceased 
patients could be enrolled into the NFCCR cohort by proxy consent from a relative). It is 
also not clear why I did not identify age as a prognostic factor in the univariate analysis, 
but it can hypothesized that the bias described for the study cohort may have a role in it. I 
did not analyze all the SNPs in these gene regions, either because they were not present 
on the Illumina SNP genotyping platform or because they failed to be genotyped in the 
patient cohort. Fifth, not all the genes functioning in the angiogenesis, lymph-
angiogenesis or metastasis pathways were investigated in relation to outcome. Sixth, the 
patient cohort consisted of Caucasian patients only, thus the results may not be relevant to 
colorectal cancer patients from other human populations. I am also aware that the MMP8 
and MMP27 SNPs, as well as of the MMP3 haplotype, found to be associated with 
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survival in the study cohort may be false-positive associations. Thus, one of the future 
research aims of our laboratory is to replicate these associations in an additional patient 
cohort previously collected between 1997-1998 in Newfoundland. 
This study also has many strengths. First, I investigated a relatively large number 
of patients compared to the majority of outcome studies previously published. Second, the 
follow-up period was relatively long, allowing us to accumulate a large number of events 
of interest (i.e. occurrence of death, recurrence and metastasis). Third, stringent quality 
control procedures were implemented to limit potentially erroneous genotype data and 
patient mix-up. Fourth, this is the first study that comprehensively examined a large 
number of polymorphisms within multiple VEGF ligand, VEGF receptor, and matrix 
metalloproteinase genes in relation to outcome in colorectal cancer. Fifth, to my 
knowledge, our laboratory is the first, if not the only, laboratory in Canada that 
investigates genetic polymorphisms as candidate prognostic markers in colorectal cancer 
(265, 306 and 307). 
 
Conclusion 
  In a cohort of colorectal cancer patients from Newfoundland, I conducted a 
candidate-pathway survival association study involving 381 polymorphisms within 30 
key angiogenesis, lymph-angiogenesis and metastasis genes. Three highly correlated 
SNPs (MMP27-rs11225388 G/A, MMP27-rs112253389 A/C, and MMP8-rs12365082 
T/A) located in two MMP genes (MMP8 and MMP27) were found to be associated with 
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overall survival independent of other prognostic markers. Analyzing the combined effects 
of SNPs in the form of haplotypes with patient outcome, I was also able to find an 
association with overall survival and a MMP3 haplotype. The biological relevance of 
these three SNP and the MMP3 haplotype to the risk of death remains to be established. 
Future studies are needed to validate these associations and to ascertain the biological 
mechanisms underlying the effects of these polymorphisms and haplotypes on survival of 
colorectal cancer patients.   
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Appendices 
Appendix A: 381 polymorphisms investigated in this study  
Genes Polymorphisms 
VEGFA rs2010963 rs3024994     
  rs25648 rs2146323     
  rs833068 rs3025010     
  rs833069 rs3025035     
  rs833070 rs3025039     
  rs3025053       
VEGFB rs11603042       
  rs4930152       
VEGFC rs2877961 rs2171083 rs3775202 rs10012721 
  rs17697359 rs1564922 rs11947611 rs13122901 
  rs1485762 rs1485768 rs3775198 rs4557213 
  rs7664413 rs6820170 rs3775195 rs10000057 
  rs1485766 rs475106 rs2333526   
PGF rs8185       
  rs12411       
VEGFR1 rs9554314 rs7332329 rs7324547 rs585421 
  rs12429309 rs9508021 rs17086609 rs7323184 
  rs9513070 rs2104330 rs1853581 rs622227 
  rs12877323 rs9319427 rs7989623 rs675923 
  rs3794397 rs9319429 rs7995976 rs655024 
  rs3794399 rs9513099 rs1408243 rs679791 
  rs2296188 rs10507384 rs9551462 rs600640 
  rs2296189 rs9513105 rs9554325 rs598945 
  rs7987291 rs11149523 rs3751395 rs17537350 
  rs7987649 rs9508034 rs17086617 rs3794405 
  rs942364 rs9513112 rs2387632 rs9513113 
  rs3794400 rs9554330 rs3936415 rs10507386 
  rs1324057       
VEGFR2 rs12642307 rs2034965 rs6828477   
  rs2125489 rs17711073 rs2168945   
  rs1531289 rs11941492 rs11732292   
  rs17709898 rs2305948 rs1870377   
  rs17085265 rs7692791 rs17085326   
  rs2219471 rs6837735     
121 
 
  rs6838752 rs12502008 rs3797104   
VEGFR3 rs307822 kgp53910 rs307823   
  rs2279622 rs2290983 rs3797102   
  rs11739750 rs10085025 rs3736061   
  rs11747066 rs4700745     
  rs10058772 rs10072977     
  rs2242217 rs307806     
  rs400330 rs11748431     
  rs1130378 rs307814     
MMP1 rs5854 rs7125062     
  rs2071230 rs470558     
  rs2239008 rs10488     
  rs470215 rs3213460     
  rs470747       
  rs1938901       
MMP2 rs1477017 rs1992116 rs2287074   
  rs865094 rs2287076 rs243843   
  rs17301608 rs11639960 rs243842   
  rs1132896 rs243836 rs183112   
  rs1053605 rs243835     
  rs866770 rs243834     
  rs9302671 rs10775332/rs14070     
  rs2241145 rs11541998     
  rs243845 rs7201     
MMP3 rs566125       
  rs3025066       
  rs3020919       
  rs679620       
MMP7 rs17886371       
  rs14983       
  rs2156528       
  rs1996352       
  rs10502001       
MMP8 rs12365082       
  rs7934972       
  rs12284255       
  rs3740938       
  rs2012390       
  rs1940475       
  rs6590984       
122 
 
  rs3765620       
  rs2155052       
MMP9 rs2274755       
  rs17576       
  rs2236416       
  rs2274756/rs17577       
  rs13925       
  rs20544       
MMP10 rs470168 rs4431992     
  rs17293348 rs2276108     
  rs470171 rs17860950     
  rs12290253 rs17293607     
  rs547561 rs486055     
  rs12272341       
MMP11 rs738791       
  rs2267029       
  rs738792       
MMP12 rs17368582       
  rs11225442       
  rs7123600       
MMP13 rs10895372       
  rs10502009       
  rs3819089       
  rs640198       
MMP14 rs1042703       
  rs762052       
  rs8006914       
  rs17243048       
  rs2236302       
  rs1042704       
  rs2236307       
  rs743257       
  rs17882342       
MMP15 rs41522747       
  rs11648508       
  rs3743563       
  rs1050779       
MMP16 rs2664369 rs10089111 rs1879201 rs2664352 
  rs2664370 rs9297422 rs17666490 rs11782395 
  rs10097366 rs1382105 rs16880099 rs1477916 
123 
 
  rs2616496 rs16878625 rs4961082 rs17664125 
  rs17719609 rs1477917 rs7826477 rs13277637 
  rs16877270 rs2664361 rs6994019 rs16878008 
  rs1477908 rs16878818 rs16880416 rs2616487 
  rs10103111 rs10099888 rs1467251 rs6469206 
  rs2616493 rs7819728 rs10955542 rs7826929 
  rs10098052 rs1996637 rs2222294 rs2616506 
  rs2664346 rs1519938 rs7817382 rs17663841 
  rs2616488 rs6981717 rs10100297 rs977231 
  rs13261974 rs13256568 rs7835845 rs7000030 
  rs6469298 rs2176771 rs9771895 rs3851539 
  rs17666351 rs1519942 rs16878034 rs10504846 
  rs13261169 rs12546847 rs4961076 rs10094702 
  rs1401861 rs17722347 rs7834743   
  rs10504847 rs4961080 rs7816934   
MMP17 rs4964924 rs9634312     
  rs4964927 rs11613757     
  rs11246838 rs11835665     
  rs6598163 rs10751704     
  rs34515698 rs12099648     
  rs10751700 rs3087864     
  rs7300198       
MMP19 rs2242295       
  rs2291267       
  rs2291268       
MMP20 rs2292730 rs1784424 rs10895322 rs2280211 
  rs11225332 rs1784423 rs1711430 rs11225344 
  rs1711399 rs3781787 rs1784430 rs1962082 
  rs1784439 rs3781788 rs1711427 rs2245803 
  rs7116339 rs17098913 rs1784425   
  rs1711433 rs10502005     
MMP21 rs7922546       
  rs10901424       
  rs12775804       
MMP24 kgp4728036 kgp7633769 kgp420199 rs11696548 
  kgp4471741 kgp9807173 rs6088776 kgp4501520 
  kgp6966600 rs2425032 rs2247828 rs6060341 
  kgp8495749 rs1205411 rs2425024 rs7280 
  kgp481229 kgp1472099 kgp7289875   
  rs12479765 rs2254207 kgp5576338   
124 
 
  rs2425022 kgp4265649 kgp10149373   
MMP25 rs2247226       
  rs10431961       
  rs7199221       
  rs1064875       
  rs1064948       
  rs11864930       
  rs10438593       
MMP26 rs2499958       
MMP27 rs2509010 rs17099425 rs2846703   
  rs11607205 rs11225386 rs3809018   
  rs1276289 rs11225388 rs4754870   
  rs11821641 rs2846707     
  rs1276286 rs1939015     
  rs2846723 rs12099177     
  rs2846701 rs11225389     
MMP28 rs3826404       
  rs10451309       
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Appendix B: Results of the univariable analysis for clinicopathological and other 
features and overall survival  
 
Variable p-value HR 
95% CI for HR 
n Lower Upper 
Age at diagnosis 0.182 1.012 0.995 1.029 504 
Sex (male vs female) 0.017 1.479 1.071 2.042 504 
Histology (mucinous vs non-
mucinous) 
0.782 0.933 0.572 1.521 504 
Location (rectum vs colon) 0.238 1.205 0.884 1.643 504 
Stage <0.001 
   
504 
Stage II vs stage I 0.222 1.42 0.809 2.493 
 Stage III vs stage I 0.003 2.313 1.335 4.008 
 Stage IV vs stage I <0.001 9.925 5.544 17.766 
 Grade (poorly differentiated vs 
well/moderately differentiated) 
0.592 0.84 0.443 1.591 500 
Vascular invasion (+ vs -) <0.001 1.71 1.251 2.336 466 
Lymphatic invasion (+ vs -) 0.005 1.564 1.148 2.132 464 
Familial risk (high/intermediate risk 
vs low risk) 
0.687 1.064 0.787 1.439 504 
MSI status (MSI-H vs MSS/MSI-L) <0.001 0.165 0.061 0.446 483 
BRAF  Val600Glu mutation (+ vs -) 0.258 0.72 0.407 1.273 457 
Adjuvant chemotherapy status (+ vs 
-) 
0.679 1.067 0.786 1.448 500 
Adjuvant 5-FU based chemotherapy 
status (+ vs -) 
0.975 1.005 0.738 1.368 490 
Adjuvant radiotherapy status (+ vs -) 0.67 1.078 0.762 1.525 487 
 
HR: hazard ratio, CI: confidence interval, n: number of patients, 5-FU 5-Fluorouracil, MSI-H: 
microsatellite instability-high, MSI-L: microsatellite instability-low, and MSS: microsatellite 
stable, (+) means present, (-) means absent.  
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Appendix C: Results of the univariable analysis for clinicopathological and other 
features and disease-free survival  
 
Variable p-value HR 
95% CI for HR 
N Lower Upper 
Age at diagnosis 0.558 1.005 0.989 1.02 503 
Sex(male vs female) 0.014 1.449 1.076 1.951 503 
Histology(mucinous vs non-
mucinous) 
0.695 0.913 0.581 1.436 
503 
Location(rectum vs colon) 0.035 1.358 1.022 1.804 503 
Stage <0.001 
   
503 
Stage II vs stage I 0.221 1.363 0.83 2.24 
 Stage III vs stage I <0.001 2.345 1.445 3.804 
 Stage IV vs stage I <0.001 5.872 3.465 9.954 
 Grade (poorly differentiated vs 
well/moderately differentiated) 
0.418 0.778 0.423 1.429 499 
Vascular invasion (+ vs -) <0.001 1.651 1.236 2.205 465 
Lymphatic invasion (+ vs -) 0.003 1.539 1.155 2.051 463 
Familial risk (high/intermediate risk 
vs low risk) 
0.296 1.16 0.878 1.533 503 
MSI status (MSI-H vs MSS/MSI-L) <0.001 0.254 0.119 0.54 482 
BRAF Val600Glu mutation  (+ vs -) 0.474 0.833 0.506 1.373 457 
Adjuvant chemotherapy status  (+ vs 
-) 
0.299 1.162 0.876 1.542 499 
Adjuvant 5-FU based chemotherapy 
status  (+ vs -) 
0.538 1.094 0.822 1.456 489 
Adjuvant radiotherapy status  (+ vs -
) 
0.146 1.262 0.922 1.727 486 
 
HR: hazard ratio, CI: confidence interval, n: number of patients, 5-FU 5-Fluorouracil, MSI-H: 
microsatellite instability-high, MSI-L: microsatellite instability-low, and MSS: microsatellite 
stable, (+) means present, (-) means absent.  
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Appendix D: Kaplan-Meier survival plots for the baseline variables associated with overall survival 
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d. Vascular invasion e. MSI status 
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Appendix E: Kaplan-Meier survival plots for the baseline variables associated with disease-free survival 
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131 
 
Appendix F: Baseline multivariable model for overall survival 
 
Variable  p-value HR 
95% CI for HR 
Lower Upper 
Sex (male vs female) 0.172 1.274 0.900 1.805 
Stage <0.001 
   Stage II vs stage I 0.111 1.614 0.896 2.906 
Stage III vs stage I 0.012 2.141 1.179 3.889 
Stage IV vs stage I <0.001 9.560 5.018 18.212 
Vascular  invasion (+ vs -) 0.372 1.168 0.830 1.643 
Location (rectum vs colon) 0.225 1.239 0.877 1.750 
MSI status (MSI-H vs MSS/MSI-L) 0.003 0.218 0.080 0.597 
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable, (+) means present, (-) means absent.  
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Appendix G: Baseline multivariable model for disease-free survival 
 
Variable p-value HR 
95% CI for HR 
Lower Upper 
Sex (male vs female) 0.22 1.221 0.887 1.68 
Stage <0.001 
   Stage II vs stage I 0.111 1.522 0.908 2.551 
Stage III vs stage I 0.005 2.103 1.245 3.555 
Stage IV vs stage I <0.001 5.648 3.152 10.12 
Vascular invasion (+ vs -) 0.425 1.138 0.828 1.564 
Location (rectum vs colon) 0.088 1.314 0.96 1.797 
MSI status (MSI-H vs MSS/MSI-L) 0.006 0.339 0.156 0.733 
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable, (+) means present, (-) means absent.  
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 Appendix H: Multivariable analysis result for the MMP3 haplotype (disease-free 
survival) (recessive genetic model)  
 
a) Adjusting for stage, and MSI status (n =482)    
     Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.126 1.488 0.895 2.474 
 Stage III vs I <0.001 2.341 1.424 3.847 
 Stage IV vs I <0.001 5.641 3.287 9.681 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.293 0.137 0.626 
 *MMP3 haplotype 0.098 0.712 0.477 1.065   
 
b) Adjusting for stage, age at diagnosis, and MSI status (n =482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.265 1.009 0.993 1.025 
 Stage <0.001    
 Stage II vs I 0.132 1.478 0.888 2.457 
 Stage III vs I <0.001 2.369 1.441 3.896 
 Stage IV vs I <0.001 5.828 3.386 10.031 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.299 0.140 0.640 
 *MMP3 haplotype 0.101 0.714 0.478 1.067   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
*patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
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 Appendix I: Multivariable analysis result for the MMP8 haplotype (disease-free 
survival) (recessive genetic model)  
 
a) Adjusting for stage, and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.133 1.476 0.888 2.455 
 Stage III vs I <0.001 2.359 1.436 3.876 
 Stage IV vs I <0.001 5.514 3.204 9.489 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.292 0.137 0.626 
 *MMP8 haplotype 0.066 1.364 0.979 1.900   
 
b) Adjusting for age at diagnosis, stage, and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.268 1.009 0.993 1.025 
 Stage <0.001    
 Stage II vs I 0.140 1.467 0.882 2.441 
 Stage III vs I <0.001 2.387 1.452 3.923 
 Stage IV vs I <0.001 5.685 3.294 9.811 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.298 0.139 0.637 
 *MMP8 haplotype 0.069 1.361 0.977 1.895   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
* patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
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Appendix J: Multivariable analysis result for the MMP21 haplotype (disease-free 
survival) (recessive genetic model)  
 
a) Adjusting for stage and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.117 1.502 0.903 2.497 
 Stage III vs I <0.001 2.343 1.426 3.850 
 Stage IV vs I <0.001 5.845 3.409 10.022 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.303 0.142 0.650 
 *MMP21 haplotype 0.098 0.719 0.486 1.062   
 
b) Adjusting for age at diagnosis, stage and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.249 1.009 0.994 1.025 
 Stage <0.001    
 Stage II vs I 0.123 1.492 0.897 2.480 
 Stage III vs I <0.001 2.370 1.442 3.896 
 Stage IV vs I <0.001 6.034 3.510 10.373 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.309 0.144 0.661 
 *MMP21 haplotype 0.095 0.717 0.485 1.059   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
* patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
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Appendix K: Multivariable analysis result for the MMP27 haplotype (overall 
survival) (recessive genetic model)  
 
a) Adjusting for stage and MSI status (n=483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.113 1.597 0.895 2.851 
 Stage III vs I 0.003 2.399 1.360 4.234 
 Stage IV vs I <0.001 9.636 5.279 17.591 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.189 0.070 0.511 
 *MMP27 haplotype 0.107 1.382 0.932 2.050   
 
b) Adjusting for age at diagnosis, stage and MSI status (n=483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.017 1.022 1.004 1.040 
 Stage <0.001    
 Stage II vs I 0.122 1.580 0.885 2.820 
 Stage III vs I <0.001 2.515 1.423 4.444 
 Stage IV vs I <0.001 10.616 5.778 19.502 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.191 0.070 0.518 
 *MMP27 haplotype 0.127 1.360 0.917 2.017   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable 
* patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
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Appendix L: Multivariable analysis result for the MMP27 haplotype (disease-free 
survival) (recessive genetic model)  
 
a) Adjusting for stage, and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.122 1.494 0.899 2.483 
 Stage III vs I <0.001 2.387 1.453 3.921 
 Stage IV vs I <0.001 5.560 3.235 9.558 
 MSI status (MSI-H vs MSS/MSI-L) <0.001 0.292 0.136 0.624 
 MMP27 haplotype 0.059 1.413 0.986 2.025   
 
b) Adjusting for stage, age at diagnosis, and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.287 1.009 .993 1.025 
 Stage <0.001    
 Stage II vs I 0.128 1.483 0.892 2.466 
 Stage III vs I <0.001 2.412 1.468 3.965 
 Stage IV vs I <0.001 5.727 3.322 9.873 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.297 0.139 0.636 
 MMP27 haplotype 0.066 1.402 0.978 2.010   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
* patients homozygous for the most common haplotype vs patients heterozygous for the most 
common haplotype or patients with the other haplotypes  
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Appendix M: Multivariable analysis result for the MMP25 haplotype (overall 
survival) (co-dominant genetic model)  
 
a) Adjusting for stage, and MSI status (n=483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.122 1.581 0.885 2.822 
 Stage III vs I 0.003 2.334 1.322 4.121 
 Stage IV vs I <0.001 9.865 5.409 17.992 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.203 0.075 0.553 
 MMP25 haplotype coding 0.194    
 *MMP25 haplotype 0.108 1.304 0.943 1.803 
 **MMP25 haplotype 0.742 0.905 0.498 1.642   
 
b) Adjusting for age at diagnosis, stage, and MSI status (n=483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.013 1.023 1.005 1.041 
 Stage <0.001    
 Stage II vs I 0.141 1.546 0.865 2.763 
 Stage III vs I 0.002 2.428 1.373 4.293 
 Stage IV vs I <0.001 10.883 5.935 19.956 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.207 0.076 0.564 
 MMP25 haplotype 0.166    
 *MMP25 haplotype 0.088 1.326 0.958 1.833 
 **MMP25 haplotype 0.763 0.912 0.502 1.657   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
*patients heterozygous for the most common haplotype vs patients with the other haplotypes; ** 
patients homozygous for the most common haplotype vs patients with the other haplotypes 
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Appendix N: Multivariable analysis result for the MMP25 haplotype (disease-free 
survival) (co-dominant genetic model)  
 
a) Adjusting for stage, and MSI status (n=482) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Stage <0.001    
 Stage II vs I 0.119 1.498 0.901 2.491 
 Stage III vs I <0.001 2.347 1.428 3.857 
 Stage IV vs I <0.001 5.804 3.380 9.966 
 MSI status (MSI-H vs MSS/MSI-L) 0.002 0.304 0.142 0.653 
 MMP25 haplotype coding 0.336    
 *MMP25 haplotype 0.243 1.193 0.887 1.606 
 **MMP25 haplotype 0.574 0.850 0.482 1.499   
 
b) Adjusting for age at diagnosis, stage, and MSI status (n=483) 
Variable p-value HR 
95% CI for HR   
Lower Upper   
Age at diagnosis 0.250 1.009 0.993 1.026 
 Stage <0.001    
 Stage II vs I 0.129 1.483 0.892 2.467 
 Stage III vs I <0.001 2.368 1.440 3.895 
 Stage IV vs I <0.001 5.989 3.478 10.313 
 MSI status (MSI-H vs MSS/MSI-L) 0.003 0.310 0.144 0.666 
 MMP25 haplotype 0.329    
 *MMP25 haplotype 0.242 1.194 0.887 1.607 
 **MMP25 haplotype 0.562 0.846 0.479 1.491   
 
HR: hazard ratio, CI: confidence interval, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable  
*patients heterozygous for the most common haplotype vs patients with the other haplotypes; ** 
patients homozygous for the most common haplotype vs patients with the other haplotypes 
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Appendix O: Clinicopathological and treatment-related features for the entire 
NFCCR cohort 
 
Entire colorectal cancer cohort (n=736) 
Variables n % 
Sex 
  Female 286 38.9 
Male 450 61.1 
Location 
  Colon 506 68.5 
Rectum 230 31.5 
Histology 
  non-mucinous 644 87.5 
Mucinous 92 12.5 
Stage 
  I 112 15.2 
II 244 33.2 
III 227 30.8 
IV 153 20.8 
Grade 
  well/moderately differentiated 651 88.4 
poorly differentiated 73 10 
Unknown 12 1.6 
Vascular invasion 
   - 398 54.1 
 + 282 38.3 
Unknown 56 7.6 
Lymphatic invasion 
   - 389 52.9 
 + 285 38.7 
Unknown 62 8.4 
Familial risk 
  Low 354 48.1 
High/intermediate 361 49 
Unknown 21 2.8 
MSI status 
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MSI-L/MSS 634 86.1 
MSI-H 73 10 
Unknown 29 3.9 
BRAF1 mutation status 
   - 589 80 
 + 80 10.9 
Unknown 67 9.1 
OS status 
  Alive 380 51.6 
Dead 355 48.2 
Unknown 1 0.2 
Median OS follow-up: 5.6 years (range: 0.04-11.12) 
DFS status 
  no recurrence/metastasis/death 348 47.2 
recurrence/metastasis/death 387 52.6 
Unknown 1 0.2 
Median DFS follow-up: 5 years (range: 0.04-11.12) 
Age 
  Median Age: 62.3 years (range: 20.7-75)   
 
OS: Overall Survival, DFS: Disease Free Survival, MSI-H: microsatellite instability-high, MSI-L: 
microsatellite instability-low, and MSS: microsatellite stable, (+) means present, (-) means absent.  
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Appendix P: Chi-square test result for the NFCCR and the study cohorts (stage) 
 
Cohort 505=1, 736=2  Stage Cross tabulation 
  
Stage 
Total 1 2 3 4 
cohort 
505=1, 
736=2) 
1 Count 93 196 166 50 505 
Expected Count 83.4 179 159.9 82.6 505 
% within cohort 
505=1, 736=2) 
18.40% 38.80% 32.90% 9.90% 100.00% 
% within Stage 45.40% 44.50% 42.20% 24.60% 40.70% 
% of Total 7.50% 15.80% 13.40% 4.00% 40.70% 
2 Count 112 244 227 153 736 
Expected Count 121.6 261 233.1 120.4 736 
% within cohort 
505=1, 736=2) 
15.20% 33.20% 30.80% 20.80% 100.00% 
% within Stage 54.60% 55.50% 57.80% 75.40% 59.30% 
% of Total 9.00% 19.70% 18.30% 12.30% 59.30% 
Total Count 205 440 393 203 1241 
Expected Count 205 440 393 203 1241 
% within cohort 
505=1, 736=2) 
16.50% 35.50% 31.70% 16.40% 100.00% 
% within Stage 100.00% 100.00% 100.00% 100.00% 100.00% 
% of Total 16.50% 35.50% 31.70% 16.40% 100.00% 
 
  
  
Chi-Square Tests 
Value df p-value 
Pearson Chi-
Square 
26.652a 3 0.000 
Likelihood 
Ratio 
28.039 3 0.000 
Linear-by-
Linear 
Association 
17.367 1 0.000 
N of Valid 
Cases 
1241     
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Appendix Q: Chi-square test result for the NFCCR and the study cohorts (vascular 
invasion) 
 
Cohort 505=1, 736=2  Vascular invasion Cross tabulation 
  
Vascular invasion 
Total 0 1 
cohort 
505=1, 
736=2) 
1 Count 308 159 467 
Expected Count 287.4 179.6 467 
% within cohort 505=1, 
736=2) 
66.00% 34.00% 100.00% 
% within Vascular invasion 43.60% 36.10% 40.70% 
% of Total 26.90% 13.90% 40.70% 
2 Count 398 282 680 
Expected Count 418.6 261.4 680 
% within cohort 505=1, 
736=2) 
58.50% 41.50% 100.00% 
% within Vascular invasion 56.40% 63.90% 59.30% 
% of Total 34.70% 24.60% 59.30% 
Total Count 706 441 1147 
Expected Count 706 441 1147 
% within cohort 505=1, 
736=2) 
61.60% 38.40% 100.00% 
% within Vascular invasion 100.00% 100.00% 100.00% 
% of Total 61.60% 38.40% 100.00% 
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Chi-Square Tests 
  Value df 
Asymp. P-
value (2-
sided) 
Exact p-
value (2-
sided) 
Exact p-
value (1-
sided) 
Pearson Chi-
Square 
6.447 1 0.011     
Continuity 
Correction 
6.137 1 0.013     
Likelihood 
Ratio 
6.485 1 0.011     
Fisher's Exact 
Test 
      0.011 0.007 
Linear-by-
Linear 
Association 
6.441 1 0.011     
N of Valid 
Cases 
1147         
 
Pearson Chi-Square p-values are bolded.  
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Appendix R: Chi-square test result for the NFCCR and the study cohorts (lymphatic 
invasion) 
 
cohort 505=1, 736=2   Lymphatic invasion Cross tabulation 
  
Lymphatic invasion 
Total 0 1 
cohort 
505=1, 
736=2) 
1 Count 298 167 465 
Expected Count 280.5 184.5 465 
% within cohort 
505=1, 736=2) 
64.10% 35.90% 100.00% 
% within Lymphatic 
invasion 
43.40% 36.90% 40.80% 
% of Total 26.20% 14.70% 40.80% 
2 Count 389 285 674 
Expected Count 406.5 267.5 674 
% within cohort 
505=1, 736=2) 
57.70% 42.30% 100.00% 
% within Lymphatic 
invasion 
56.60% 63.10% 59.20% 
% of Total 34.20% 25.00% 59.20% 
Total Count 687 452 1139 
Expected Count 687 452 1139 
% within cohort 
505=1, 736=2) 
60.30% 39.70% 100.00% 
% within Lymphatic 
invasion 
100.00% 100.00% 100.00% 
% of Total 60.30% 39.70% 100.00% 
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Chi-Square Tests 
  Value df 
Asymp. P-
value (2-
sided) 
Exact p-
value (2-
sided) 
Exact p-
value (1-
sided) 
Pearson Chi-
Square 
4.666 1 0.031     
Continuity 
Correction 
4.404 1 0.036     
Likelihood Ratio 4.686 1 0.03     
Fisher's Exact 
Test 
      0.031 0.018 
Linear-by-Linear 
Association 
4.662 1 0.031     
N of Valid Cases 1139         
 
Pearson Chi-Square p-values are bolded.  
 
  
147 
 
Appendix S: Non-parametric Mann-Whitney U-test results comparing median age, 
overall survival and disease-free survival times for the NFCCR and the study cohort 
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Appendix T: Spearman correlation test results for nine of the SNPs in the LD blocks 14 and 15 (Figure 4.1)  
Correlations 
  
MMP27_
rs112253
88_A_G 
MMP27_r
s2846707
_G_A 
MMP27_rs
1939015_A
_G 
MMP27_rs1
2099177_G
_A 
MMP27_rs1
1225389_C
_A 
rs1241
8360_
C 
MMP8_rs1
2365082_T
_A 
MMP8_rs7
934972_G
_A 
MMP8_rs1
2284255_C
_A 
Spea
rman
's rho 
MMP27_rs1
1225388_A
_G 
Correlati
on 
Coefficie
nt 
1 .796
**
 -.291
**
 -.166
**
 .999
**
 0.014 .997
**
 -.178
**
 -.179
**
 
Sig. (2-
tailed) 
  0 0 0 0 0.758 0 0 0 
N 505 505 505 505 505 505 505 505 504 
MMP27_rs2
846707_G_
A 
Correlati
on 
Coefficie
nt 
.796
**
 1 .143
**
 -.186
**
 .795
**
 0.015 .794
**
 -.236
**
 -.237
**
 
Sig. (2-
tailed) 
0   0.001 0 0 0.741 0 0 0 
N 505 505 505 505 505 505 505 505 504 
MMP27_rs1
939015_A_
G 
Correlati
on 
Coefficie
nt 
-.291
**
 .143
**
 1 -0.066 -.292
**
 -0.024 -.289
**
 .621
**
 .621
**
 
Sig. (2-
tailed) 
0 0.001   0.138 0 0.597 0 0 0 
N 505 505 505 505 505 505 505 505 504 
MMP27_rs1
2099177_G
_A 
Correlati
on 
Coefficie
nt 
-.166
**
 -.186
**
 -0.066 1 -.166
**
 -0.009 -.164
**
 -0.039 -0.04 
Sig. (2-
tailed) 
0 0 0.138   0 0.846 0 0.379 0.376 
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N 505 505 505 505 505 505 505 505 504 
MMP27_rs1
1225389_C
_A 
Correlati
on 
Coefficie
nt 
.999
**
 .795
**
 -.292
**
 -.166
**
 1 0.019 .996
**
 -.178
**
 -.179
**
 
Sig. (2-
tailed) 
0 0 0 0   0.678 0 0 0 
N 505 505 505 505 505 505 505 505 504 
rs12418360
_C 
Correlati
on 
Coefficie
nt 
0.014 0.015 -0.024 -0.009 0.019 1 0.015 -0.026 -0.027 
Sig. (2-
tailed) 
0.758 0.741 0.597 0.846 0.678   0.736 0.554 0.55 
N 505 505 505 505 505 505 505 505 504 
MMP8_rs12
365082_T_
A 
Correlati
on 
Coefficie
nt 
.997
**
 .794
**
 -.289
**
 -.164
**
 .996
**
 0.015 1 -.176
**
 -.177
**
 
Sig. (2-
tailed) 
0 0 0 0 0 0.736   0 0 
N 505 505 505 505 505 505 505 505 504 
MMP8_rs79
34972_G_A 
Correlati
on 
Coefficie
nt 
-.178
**
 -.236
**
 .621
**
 -0.039 -.178
**
 -0.026 -.176
**
 1 1.000
**
 
Sig. (2-
tailed) 
0 0 0 0.379 0 0.554 0     
N 505 505 505 505 505 505 505 505 504 
MMP8_rs12
284255_C_
A 
Correlati
on 
Coefficie
nt 
-.179
**
 -.237
**
 .621
**
 -0.04 -.179
**
 -0.027 -.177
**
 1.000
**
 1 
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Sig. (2-
tailed) 
0 0 0 0.376 0 0.55 0     
N 504 504 504 504 504 504 504 504 504 
 
Green highlight = the correlation of the SNP genotypes are extremely high (rs >0.99), Red font = SNP genotypes are highly correlated (rs = 
0.8) 
